Biomarkers for metabolic drug activation : towards an integrated risk assessment for drug-induced liver injury (DILI) by Teppner, Marieke
  
Biomarkers for Metabolic Drug Activation: 
Towards an Integrated Risk Assessment for 
Drug-Induced Liver Injury (DILI) 
 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
 
Marieke Teppner 
 
 
aus Kiel, Deutschland 
 
 
 
Basel, 2016 
 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
  
  
 
 
Genehmigt von der Philiosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
 
 
 
Fakultätsverantwortlicher: Prof. Dr. Beat Ernst 
Dissertationsleiter: Dr. Axel Pähler 
Ko-Referent: Dr. Amit Kalgutkar 
 
 
 
Basel, 22.04.2014 
 
 
 
Prof. Dr. Jörg Schibler 
Dekan 
 
Table of Contents I 
 
TABLE OF CONTENTS 
TABLE OF CONTENTS I 
ACKNOWLEDGEMENT V 
ABBREVIATIONS VII 
1 INTRODUCTION 1 
1.1 Background 1 
1.2 The liver in context of drug metabolism 2 
1.3 Drug-induced liver injury (DILI) 4 
1.3.1 Definition of DILI 4 
1.3.2 Mechanistic hypotheses 6 
1.3.3 Risk factors for DILI 9 
1.3.4 Oxidative stress as risk factor for DILI 11 
1.3.5 Drug examples 13 
1.4 Tools for investigation of metabolism and drug safety 16 
1.4.1 Hepatic in vitro systems for drug metabolism 16 
1.4.2 Reactive metabolite assessment 17 
1.4.3 Investigation of cellular oxidative stress and related toxicity 18 
1.4.4 DILI in drug development: Screening approaches 19 
1.5 References 21 
2 OBJECTIVE OF THE WORK 25 
3 RESULTS AND DISCUSSION 27 
3.1 The value of bioactivation assessment for the prediction of DILI 27 
3.2 Characterization and validation of biomarkers for cellular oxidative stress 63 
3.2.1 Validation of isoprostanes as in vitro biomarkers for oxidative stress 63 
3.2.2 Application of isoprostane determination using flutamide as a DILI model compound 75 
3.2.3 Comparison of oxidative stress markers in rodents using flutamide                                       
as a DILI model compound 83 
4 SUMMARY AND OUTLOOK 95 
5 ZUSAMMENFASSUNG UND AUSBLICK 99 
  
 
III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis is presented in the form of four scientific papers that are published or in 
preparation for publication. Reference lists can be found at the end of each result 
chapter. 
 
Acknowledgement V 
 
ACKNOWLEDGEMENT 
I would like to express my gratitude towards all people at the Pharmaceutical 
Sciences department at Roche Basel who supported me and my work with a lot of 
helpfulness and kindness. 
Especially, I would like to thank Dr. Axel Pähler for giving me the opportunity to 
perform this exciting project under his supervision and for his continuous support, 
advice and discussions during the last three years. 
Many thanks go to Prof. Beat Ernst for accepting to be my academic supervisor and 
reviewing my work. 
I am very grateful to Dr. Amit Kalgutkar for being the co-referee of this thesis. 
Special thanks go to the people who contributed to my work with their scientific 
knowledge: Dr. Fränzi Böss, Dr. Tobias Heckel and Isabelle Walter were always 
ready for help and discussions around experimental and analytical questions. 
Dr. Holger Fischer, Dr. Neil Parrott and Dr. Antonello Caruso supported me with 
respect to mathematical, statistical and modeling questions. 
Also, I would like to acknowledge Sandrine Simon, Aynur Ekiciler, Nathalie Schaub 
and Evelyne Durr for their help with hepatocyte isolation and handling as well as 
Andreas Goetschi for sharing his broad instrumental and analytical knowledge. 
Everybody from the drug metabolism group was especially helpful to give advice and 
solve scientific, technical and personal trouble. Andreas, Bernd, Christophe, Kirsten, 
Manfred, Michaela, Russell, Ruth and Thomas: thanks for being great colleagues. 
Special thanks go to Dr. Kajsa Kanebratt for introducing and inspiring me for 
scientific work. 
I would like to acknowledge all members of the Molecular Pharmacy and Molecular 
Modeling at the University of Basel for welcoming and accepting me as a member of 
their group. 
Finally, I would like to thank my family and Michel for their constant support, patience 
and encouragement. 
 
Abbreviations VII 
 
ABBREVIATIONS 
 
 
15R-PD2 15R prostaglandin D2 
8,12-iso- 8,12-iso- 
   iPF2α-VI  isoprostane F2α-VI 
ADH  Aldehyde dehydrogenase 
AKR  Aldo-keto reductase 
ALT  Alanine aminotransferase 
APC antigen presenting cell 
ARE Antioxidant response element 
AST  Aspartate aminotransferase 
BSEP  Bile salt export pump 
CCl4  Carbon tetrachloride 
CE  Collision energy 
CES1  Carboxylesterase 1 
CID  Collision-induced dissociation 
CL  Clearance 
CLint  Intrinsic clearance 
CVB  Covalent protein binding 
CXP  Cell exit potential 
CYP  Cytochrome P450 
DHN-MA 1,4-dihydroxy-2(E)-nonene 
mercapturic acid 
Dihydro-keto 13,14-dihydro-15-keto 
   PD2 prostaglandin D2 
Dihydro-keto 13,14-dihydro-15-keto 
   PE2 prostaglandin E2 
DILI  Drug-induced liver injury 
DILIN Drug-induced liver injury 
network 
DNA  Deoxyribonucleic acid 
DP  Declustering potential 
ECH erythroid cell-derived protein 
with CNC homology 
EIA  Enzyme immunoassay 
EPI  Enhanced product ion 
ER  Enhanced resolution 
ESI  Electrospray ionization 
F  Bioavailability 
Fa  Fraction absorbed 
FDA Food and drug administration 
FDp Fraction of dose reaching the 
portal vein 
Fe(III)NTA Ferric nitrilotriacetic acid 
fm  Fraction metabolized 
FMO Flavin-containing 
monooxygenase 
Foral  Oral bioavailability 
GC  Gas chromatography 
GCLC   Glutamate-cysteine ligase 
GLDH  Glutamate dehydrogenase 
GSH  Glutathione 
GST Glutathione-S-transferase 
HIV Human immunodeficiency 
virus 
HLA  Human leukocyte antigen 
HLM  Human liver microsomes 
HMG-CoA 3-Hydroxy-3-methylglutaryl-
coenzyme A 
HMOX Heme oxygenase 
HNE 4-Hydroxy-2(E)-nonenal 
HNE-MA HNE mercapturic acid 
HPLC high performance liquid 
chromatography 
HRP  Horseradish peroxidase 
HSP  Heat shock protein 
Iav  Systemic concentration 
IDILI Idiosyncratic drug-induced 
liver injury 
Iin  Liver inlet concentration 
INR International normalized ratio 
IgE  Immunoglobulin E 
iPF2α-III  8-isoprostane F2α 
iPF2α-VI 5-iso prostaglandin F2α-VI 
IVIVC  In vitro-in vivo correlation 
ka  Absorption constant 
Keap1 Kelch-like ECH-associated 
protein 1 
VIII Abbreviations 
LC Liquid chromatography 
LC-MS/MS Liquid chromatography / 
tandem mass spectrometry 
LDH  Lactate dehydrogenase 
LLE  Liquid liquid extraction 
LM  Liver microsomes 
LogD  Distribution coefficient 
logP  Partition coefficient 
LOQ  Limit of quantification 
LPS  Lipopolysaccharide 
MA Mercapturic acid 
MDA  Malondialdehyde 
mEH Microsomal epoxide hydrolase 
MHC Major histocompatibility 
complex 
MIP-DILI Mechanism based integrated 
systems for the prediction of 
drug-induced liver injury 
MPO Myeloperoxidase 
mRNA  Messenger RNA 
MRP2 Multi-drug resistance protein 2 
MS  Mass spectrometry 
MS/MS Tandem mass spectrometry 
NaNTA  Nitrilotricacetic acid sodium 
NAT N-Acetyl transferase 
NICI Negative ion chemical 
ionization 
NPV  Negative predictive value 
NQO NAD(P)H:quinone 
oxidoreductase 
Nrf2 Nuclear factor erythroid 2-
related factor 1 
NSAID Non-steroidal anti-
inflammatory drug 
PGZ Pioglitazone 
PD2  Prostaglandin D2 
PD2-d4  deuterated Prostaglandin D2 
PE2  Prostaglandin E2 
PF2α  Prostaglandin F2α 
P-I Pharmacological interaction 
PI  Precursor ion 
PLA-DA Partial least squares 
discriminant analysis 
PPARγ Peroxisome proliferator-
activated receptor gamma 
PSA  Polar surface area 
QC  Quality control 
Qh  Hepatic bloodflow 
UDP  Uridine diphosphate 
UGT UDP-glucuronosyl transferase 
ULN  Upper limit of normal 
R2  Coefficient of determination 
RGZ  Rosiglitazone 
RM  Reactive metabolite 
ROS  Reactive oxygen species 
SD  Standard deviation 
SDH  Sorbitol dehydrogenase 
SOD  Superoxide dismutase 
SPE  Solid phase extraction 
SRM  Selected reaction monitoring 
SULT  Sulfotransferase 
TGZ  Troglitazone 
XO  Xanthine oxidase 
Introduction 1 
 
1 INTRODUCTION 
1.1 Background 
Drug-induced liver injury (DILI) is one of the major reasons for severe adverse 
reactions upon therapeutic drug intake today. It has led to many cases of drug attrition, 
withdrawal or restricted usage and is the leading cause of acute liver failure [8-10]. 
Promising innovative medications like the antidiabetic troglitazone and the 
anticoagulant ximelagatran had to be removed from the market shortly after approval. 
Other drugs like the antituberculotic isoniazid and the anticonvulsant valproate were 
labeled with a black box warning which controls and limits their prescription. Case 
estimates of DILI are around 19 per 100’000 treated individuals [11]; however, it is 
supposed that these numbers suffer from large underreporting [12]. Heterogeneous 
symptoms, delayed onset, lack of dose dependence and incomplete awareness of 
contributing risk factors hinder control and diagnosis of liver toxicity. A large impact on 
patients’ health and on pharmaceutical industry and a challenge for authorities and 
scientific community is the result. Many efforts to understand mechanisms and 
develop mitigation strategies have been undertaken by researching companies and 
academia. Even holistic collaborative networks have been founded to better monitor 
DILI and explore approaches for improved safety [13, 14]. 
To improve risk assessment and promote causality elucidation, it is important to 
understand underlying physiological processes and their interaction with an 
administered drug. Therefore, the current understanding of DILI will be explored in the 
following sections and put into context with relevant body functions, available test 
systems and analytical markers. 
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1.2 The liver in context of drug metabolism 
The liver is the most important organ for metabolic activity and the biggest exocrine 
gland in the human body. It is located centrally in the torso and well connected to the 
blood flow by two afferent vessels, the Arteria hepatica and the Vena portae, which 
transport arterial (A. hepatica) and venous blood (V. portae) from the unpaired 
abdominal viscera. Following the passage of the hepatic capillary system, the blood is 
released through the Vena hepatica and the Vena cava inferior to systemic circulation 
(Figure 1.1A). With its gate-keeping function the liver has various responsibilities. 
Important ones are synthesis and breakdown of endogenous substrates in 
carbohydrate, protein and lipid metabolism as well as regulation of coagulation and 
hormone homeostasis. Besides, it is essentially involved in the process of 
detoxification and excretion of xenobiotics. 
The liver tissue is composed by different cell types, non-parenchymal cells (sinusoidal 
endothelial cells, Kupffer cells, and stellate cells) and parenchymal cells, the 
hepatocytes. With 80% of total volume, the latter represent the largest cell population 
of the liver and are its most important functional subunit. The enzymatic equipment for 
biotransformation of most xenobiotic compounds is located here; catalysis of drug 
modifications to more hydrophilic species enables their excretion via bile or urine. 
Biotransformation is generally divided into two phases, an activating (phase I) and a 
conjugating step (phase II). Activation of chemical entities can be achieved by 
hydrolytic, reductive, or oxidative processes. The most frequent pathway is the 
oxidation of alkylated heteroatoms or aromatic / hydroxylated functions, predominantly 
catalyzed by monooxygenases of the cytochrome P450 (CYP) enzyme superfamily. 
Other phase I drug-metabolizing enzymes are flavin-containing monooxygenases 
(FMO), alcohol / aldehyde oxidases (oxidation), esterases, epoxide hydrolases 
(hydrolysis) and NADPH-cytochrome P450 reductases (reduction). To enable 
elimination activated species are then mostly coupled to hydrophilic endogenous 
substances such as glucuronic acid, sulfonic acid or glutathione (GSH) by transferases 
[15]. 
Metabolism of xenobiotics during the first liver passage can prevent or reduce their 
systemic circulation and is therefore called “first pass effect”. It can result into 
decreased plasma levels or bioavailability, but also support the activation of a pro-
drug. 
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Functionality of the hepatocytes are closely related to the histo-anatomic architecture 
of the liver lobes: An oxygen gradient between portal triad (hepatic artery, hepatic 
portal vein, bile duct) and the central hepatic vein defines different metabolic zone 
within the hepatocytes along the sinusoid with decreasing oxidative activity 
(Figure 1.1B). 
In summary, the liver is a particular target for xenobiotic respectively drug action 
and effects, but even more importantly for interactions and side effects. All blood from 
the gastrointestinal tract, containing orally absorbed drug, passes the liver with the 
potential of first metabolic interaction. Clearance of an active compound from the 
systemic circulation is prepared via biotransformation in the liver. Direct effects of a 
xenobiotic or those of a metabolite bear the potential of harming the liver, e.g. by 
altering functions or triggering immune response. 
 
 
 
Figure 1.1: Functional macro- and microanatomy of the liver 
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1.3 Drug-induced liver injury (DILI) 
1.3.1 Definition of DILI 
Drug-induced liver injury (DILI) is defined as an adverse effect upon drug intake at 
therapeutic doses. It may cause pathophysiological or pathological alterations of liver 
parameters or liver function with diverse severity. Many contributing factors to DILI 
remain unclear today. Thus, the term ‘DILI’ and its diagnosis are mainly characterized 
by exclusion of other possible etiologies except for the side effect of an administered 
xenobiotic agent. It is characterized by time to onset, clinical features, course of 
recovery, specific risk factors, previous reports on hepatotoxicity of the implicated 
agent and can be supported by knowledge on effects after rechallenge and liver biopsy 
[16]. It is widely accepted that environmental factors such as comedications and host 
factors such as genetic predisposition and underlying disease impact the 
manifestation of DILI to at least the same extent as the liability of the drug itself do. 
Significant clinical DILI determinants are either changes in the hepatic biomarker 
status or functional loss. The former comprise of 5-fold elevation of aspartate 
transaminase (AST) or alanine transaminase (ALT) as compared to the upper limit of 
normal (ULN) or 2-fold elevations in either alkine phosphatase or bilirubin plus any rise 
in ALT or AST levels [17]. The latter arise from degenerative processes with steatotic, 
cholestatic, cirrhotic, or necrotic characteristics [18]. Hyman Zimmerman observed a 
correlation between the occurrence of jaundice and fatality of DILI. On this basis, the 
FDA defined “Hy’s law” as predictor for fatal hepatotoxicity with bilirubin levels higher 
than 2 mg/mL and AST / ALT higher than 3-times ULN [19]. An overview on different 
DILI phenotypes is given in Table 1.1, illustrating that it can mimic various types of 
liver injury, and even one drug may cause different clinical pattern. E.g. Isoniazid is 
known to cause three types of acute liver impairment as well as chronic hepatitis [20]. 
The term DILI is often accompanied by the attribute ‘idiosyncratic’ (also IDILI), literally 
meaning ‘mixture of characteristics’. This expression points towards the unpredictable 
character of these adverse effects. They lack dose dependence, occur in low 
incidence, cannot be addressed in animal models and are therefore not detected in 
drug discovery. Fatalities in patients, high therapeutic costs for the health care system 
and economic damage for the pharmaceutical industry are the consequences. 
Consequently drug developing companies but also health care authorities and the 
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scientific community are highly interested in improving mechanistic understanding and 
safety assessment of new drugs. Dedicated projects in industry are promoted, 
research groups in academia investigate underlying mechanisms and even holistic 
collaborations have been launched: a drug-induced liver injury network (DILIN) was 
initiated by the US National Institute of Diabetes and Digestive and Kidney Diseases 
aiming for a better documentation and critical review of hepatotoxicity cases [13] and 
project called MIP-DILI (mechanism-based integrated systems for the prediction of 
drug-induced liver injury) was launched as a collaboration between academia and 
industry, supported by the European [14]. Both aim for a better documentation, 
understanding and improved analytical tools for liver toxicity. 
 
Table 1.1: Clinical phenotypes of DILI adopted from [18] 
Phenotype Characteristics  Example drug 
Immunoallergic hepatitis skin rash, eosinophilia, fever phenytoin 
autoimmune hepatitis-like autoantibodies detectable nitrofurantoin 
acute hepatic necrosis parenchymatic necrosis isoniazid 
acute viral hepatitis-like fatigue isoniazid 
Acute liver failure parenchymatic necrosis,  INR > 1.5, encephalopathy bromfenac 
cholestatic hepatitis alkaline phosphatase and  bilirubin elevations amoxicillin clavulanate 
bland cholestasis pruritis  anabolic steroids 
acute fatty liver  
with lactic acidosis 
steatosis,  
mitochondrial dysfunction valproate 
nonalcoholic fatty liver steatosis (steatohepatitis) Amiodarone 
sinusoidal obstruction syndrome obliteration of central veins cyclophosphamide 
chronic hepatitis fatigue, bilirubin elevation 
 necrosis isoniazid 
nodular regeneration formation of nodules azathioprine 
vanishing bile duct syndrome loss of interlobular bile ducts,  
cholestasis β-lactam antibiotics 
cirrhosis collagenization methotrexate 
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1.3.2 Mechanistic hypotheses 
Different hypotheses have been established which try to explain the heterogeneous 
pattern of DILI. None of them is currently able to describe all cases of drug induced 
hepatotoxicity; however, for individual examples they may apply. 
 
Bioactivation 
Bioactivation is widely accepted as important contributing factor to the pathogenesis 
of hepatotoxicity. In situations where reactivity of phase I metabolites is too high or 
phase II substrates are depleted, they are prone to bind to any partner of matching 
nucleophilicity in immediate vicinity. Less frequently, also phase II metabolism can 
lead to bioactivation. E.g., the glucuronic acid in acyl glucuronides displays a good 
leaving group which can be substituted by an amino acid residue. For instance, this 
mechanism was observed in non-steroidal anti-inflammatory drugs (NSAIDs). They 
contain free carboxylic acid moieties that can be conjugated via UDP glucuronosyl 
transferases (UGTs) [21]. 
Drugs that directly impair function of macromolecules upon binding are alkylating 
cytostatic agents. They contain structural elements that can be activated to carbo-
kations and are prone to react with nucleic acids which disables their reduplication by 
crosslinking or disruption of DNA strands. This is pharmacologically intended to stop 
tumor growth; however, unspecific reactivity can be responsible for various adverse 
effects on proliferating tissues [22]. A prominent example is cyclophosphamide, an 
anticancer drug used for treatment of many types of tumors. Its alkylating principle is 
phosphoramide mustard, which is generated from the pro-drug after CYP2B6-
mediated activation and subsequent non-enzymatic cleavage [23]. As shown in 
Figure 1.2, also other alkylating by-products emerge from this pathway, exhibiting non-
target effects. One of them is acrolein, which is renally cleared and prone to react with 
bladder epithelia, resulting in cystitis or even cancer [24]. Adverse effects in liver and 
heart may also be mediated via formation of covalent DNA or enzyme adducts and 
GSH depletion by acrolein [25, 26]. 
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Figure 1.2: Metabolic pathways and bioactivation of cyclophosphamide 
 
Hapten hypothesis 
Covalent modifications on proteins can result in direct functional impairment or loss 
but also in neoantigen formation. The novel adduct, unknown to the body, is able to 
trigger immunogenicity which involves uptake of the modified protein by antigen 
presenting cells (APC), hydrolytic processing and surface presentation in the major 
histocompatibility complex to T cells. This process activates the immune cascade 
including autoantibody formation and was observed for the first time by Landsteiner. 
He detected that small molecules could only act as immunogens when bound to 
proteins and are thus referred to as ‘haptens’ [27, 28]. 
Relevance of this hypothesis was demonstrated for antibiotics of the penicillin family. 
Their β lactam ring is a target for nucleophilic attack by free amino groups of proteins 
resulting in ring opening and covalent adducts formation mainly with the generated 
penicilloyl group. These adducts are known to trigger formation of specific IgE 
antibodies and thus to mediate allergic reactions [29, 30]. 
 
Danger hypothesis 
Drugs such as raloxifen, simvastatin and olanzapine form covalent protein adducts 
[3, 31], however, they do not cause idiosyncratic reactions. Hence, another hypothesis, 
called “danger hypothesis”, was formulated by P. Matzinger. She postulated the 
necessity of a danger signal in addition to the modified protein to trigger 
immunogenicity. She refers to the fact that also during physiological defense a 
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secondary stimulation of T-cells is needed to activate APCs and initiate immune 
response instead of tolerance [32]. This danger signal might be triggered by e.g. 
cellular stress from reactive drug metabolites, heat shock proteins (HSP) or bacterial 
endotoxins such as lipopolysaccharide (LPS) from underlying infections [33, 34]. 
 
Pharmacological interaction (P-I) hypothesis 
A third important theory is based on Pichler’s observation that drug-exposed cloned T 
cells proliferated in absence of metabolic activity [35]. He presumed that some drugs 
can bind directly to the MHC T cell receptor complex and provoke an immune response 
without any preceding metabolic activation, binding to free proteins or digestion by 
APCs. An example for this hypothesis is sulfamethoxazole which was shown to be 
presented in an unstable, but MHC-restricted fashion independent of processing [36]. 
The name P-I hypothesis derives from the suggestion that a drug can interact directly 
as pharmacological agent with the immune receptor [37]. 
 
 
 
Figure 1.3: Key mechanistic hypotheses for idiosyncratic drug reactions: Bioactivation 
or intrinsic activity of a drug leads to binding to residues of free proteins or the T-cell 
receptor and triggers an immune response. Adopted from Uetrecht, ‘Idosyncratic Drug 
reactions: Current Understanding’ [38]. 
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Non immune hypotheses 
Besides the discussed theories there are other mechanistic concepts describing 
examples where characteristics for hypersensitivity reactions are not present. For 
these cases, mitochondrial impairment or presence of an inflammagen such as 
lipopolysaccharides (LPS) is discussed as risk factors [39, 40]. 
 
Despite these theories, important mechanistic knowledge to explain unexpected drug 
reactions is missing and only individual examples fit to the given explanations, even 
though, as stated by Uetrecht, hypotheses are not mutually exclusive. Reactive 
intermediates might act as danger signal on top of being a hapten [38]. An overview 
of the three most important hypotheses is shown in Figure 1.3. 
 
1.3.3 Risk factors for DILI 
Various factors are discussed to contribute to the pathogenesis of DILI in susceptible 
individuals in contrast to tolerant ones. These comprise of characteristics of the drug 
itself (pharmacokinetics and -dynamics), environmental factors (e.g. diet or 
comedication) and, probably of major importance, host dependent risk factors, both 
genetic and non-genetic ones. An overview is given in Table 1.2. 
The influence of gender or age as susceptibility factor for DILI has been assessed in 
several studies with no clear evidence for increased risk in one demographic 
subpopulation. Even though some investigations found women at higher risk than men 
[41, 42] and children as compared to adults [43, 44], these did not correct for 
differences in patient prevalence and disease incidence / medication profile for the 
different patient groups [45, 46]. Also dietary liabilities, like alcohol or tobacco 
consume as source of liver stress or inflammation factors have not been clearly 
matched with increased susceptibility [47]. 
Drug related risk factors, in contrast, are characterized in a more substantial manner. 
Compounds given at less than 50 mg per day in contrast to higher dosing regimens 
lack the risk of liver impairment [48]. This observation by Lammert et al. implicates that 
idiosyncrasy, in contrast to general belief, is dose dependent, but saturated at 
concentrations where a dose-response for effects are seen. 
Lammert also reported a correlation between increased incidence for adverse effects 
and a high degree (>50%) of hepatic metabolism [49]; specifically, metabolism via 
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CYP2C9 and CYP2C19 was found to be associated with increased risk as compared 
to transformation via other CYPs [50]. This may be due to their polymorphic character, 
i.e. in differences in catalytic activity. Toxicity of tienilic acid for example is mediated 
by metabolic activation via CYP2C9: Its oxidized metabolite readily inactivates the 
enzyme by formation of covalent adducts [51]. Circulating antibodies against CYP2C9 
drug conjugates were found to be responsible for the autoimmune response of 
affected patients [52]. Moreover, polypharmacy represents a risk for pharmacokinetic 
interactions, such as potentiated effects of two drugs that are eliminated over the same 
pathway [18]. E.g., co-administration of cerivastatin and fibrates enhanced the risk of 
rhabdomyolysis and resulted in the withdrawal of the HMG-CoA inhibitor cerivastatin. 
It is meanwhile known that adverse effects were caused by increased plasma levels 
due to inhibition of CYP3A4. 
Also, patients exposed to comedications often suffer from underlying diseases which 
can modulate the risk for toxicity, especially when the liver is affected e.g. by hepatitis 
or HIV. However, data quality on this aspect is poor and does not allow definite 
conclusions [47]. 
 
Table 1.2: Overview of contributing factors for idiosyncratic drug reactions 
Risk factor Example Involved drug 
Drug class /structural 
alert 
Primary aromatic amine 
moiety sulfamethoxazole 
Exposure Dose Metabolic pathways troglitazone, pioglitazone 
Co-medication drug-drug interactions at DM 
enzymes ketoconazole, terfenadin  
genetic difference of 
enzyme equipment CYP2C polymorphism tienilic acid 
Genetic differences of 
the immune system HLA genotype lumiracoxib 
 
In the last decades improved analytical tools and method allowed for a more in-depth 
analysis of genetic differences in patients. Mainly polymorphic proteins resp. enzymes 
involved in drug metabolism have been identified as risk factors. Differences in 
expression of the phase II detoxifying enzymes N acetyl transferase (NAT) and  S 
transferase (GST) as well as polymorphic CYP enzymes (e.g. CYP2D6, CYP2C9, as 
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mentioned above) can influence the metabolic pattern and thus a drug’s safety. 
Moreover, interindividual differences in the immune response via specific human 
lymphocyte antigen (HLA) variations co-determine tolerance or occurrence of 
idiosyncratic reactions. One of the best studied example in this context is abacavir-
induced hypersensitivity, which is correlated to the HLA B*5801 genotype [53]. Other 
drugs bearing increased risk in patients with specific HLA types are lumiracoxib, 
ximelagatran and amoxicillin-clavulanate [54-56]. However, the lumiracoxib example 
also shows limitations of isolated consideration of the HLA liabilities: Selection of 
patients based on this criterion results in a massive over-exclusion, as 94.4% of 
patients with the respective HLA type do not develop liver toxicity [54]. 
 
1.3.4 Oxidative stress as risk factor for DILI 
During oxidative stress the balance between oxidant and antioxidant forces in the body 
is disturbed. The liver is especially sensitive to this disturbance as some of its major 
functions include handling reactive oxygen species (ROS): Activation of molecular 
oxygen to superoxide during mitochondrial ATP production can form hydrogen 
peroxide (H2O2) or hydroxyl radicals (OH•), biotransformation of xenobiotics by 
monooxygenase enzymes produces H2O2 and superoxide as byproducts, 
physiological immune defense involves peroxisomal H2O2 formation in hepatocytes 
and superoxide generation in Kupffer cells and neutrophils [57, 58]. These reactive 
species can readily react with nucleophilic structures in proximity, i.e. proteins, DNA 
and lipids which may then be altered in function [59]. Modification of sulfhydryl and 
aromatic moieties in proteins may induce harmful conformational changes, oxidation 
of mitochondrial DNA can cause interference for transcription, and lipid peroxidation 
may result in reduced membrane integrity. E.g., OH•-catalyzed lipid peroxidation 
generates peroxy intermediates which can recruit further fatty acids for oxidation and 
thus initiate a chain reaction. This process has been demonstrated for carbon 
tetrachloride toxicity [60] and can result in serious membrane damage and even 
inflammatory effects via activation of stellate cells [61]. 
In physiological conditions pro-oxidant processes are balanced by the antioxidant 
response pathway, a cellular, gene regulated protection mechanism against radical-
induced damage [62], as depicted in Figure 1.4: The cytosolic Kelch-like 
ECH-associated protein 1 (Keap1) suppresses the nuclear factor erythroid 2-related 
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factor 2 (Nrf2), a transcription factor, in the normal state. However, under oxidative 
stress conditions Nrf2 is released, translocates to the nucleus and binds to a DNA 
promotor sequence, the antioxidant response element (ARE). This triggers 
transcription of the affected genes, encoding for cytoprotective proteins such as 
detoxifying phase II enzymes and antioxidants to support inactivation of endogenous 
and xenobiotic reactive species. Examples are aldo-keto reductases (AKR), heme 
oxygenases (HMOX), microsomal epoxide hydrolases (mEH), NADPH:quinone 
oxidoreductases (NQO), UGTs, superoxide dismutases (SOD) and various enzymes 
involved in GSH metabolism. GSH (γ-L-glutamyl-L-cysteinylglycine) is the most 
important free radical scavenger in the human body; with its intracellular concentration 
of up to 10 mM it supports spontaneous and enzymatic detoxification and regeneration 
via its reactive thiol group [63]. 
However, when the oxidative stress is too excessive, cellular defense mechanisms 
may be insufficient: Examples are the intake of > 4 g acetaminophen which depletes 
the GSH pool by adduct formation with the iminoquinone metabolite or menadione-
induced redox cycling which is mediated by P450 reductase-catalyzed formation of 
radicals, followed by regeneration of parent [64, 65]. In these cases free radicals 
cannot be managed anymore and pathophysiological changes occur. 
 
Figure 1.4. Activation of Nrf2 as redox sensitive signaling factor. Ubiquitination of Nrf2 
results in cleavage of the Nrf2-Keap1 complex and translocation to the nucleus. As a 
heterodimer with Maf, Nrf2 binds to ARE and activates transcription. Adapted by 
permission from Macmillan Publishers Ltd: Nat Rev Drug Discov (Ref [66]) copyright 
(2005). 
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1.3.5 Drug examples 
Many DILI drugs that were investigated with respect to their toxicity mechanism 
possess several liabilities that may contribute to their safety profile. This complicates 
identification of susceptible discovery drugs and discrimination from safe analogues. 
Diclofenac and troglitazone are examples where toxicity most likely results from the 
interplay of some of the discussed risk factors. 
Diclofenac 
Diclofenac is an NSAID widely prescribed against rheumatoid disorders. However, it 
is associated with liver injury and liver failure [67, 68] which was not predicted in animal 
models nor correlated to the dose. Mechanistic investigations identified several drug-
related liabilities for toxicity which are summarized in Figure 1.5. 
Diclofenac undergoes CYP2C9- and CYP3A4-catalyzed hydroxylation of its aromatic 
rings in para-position to the imino group. Further P450- and MPO-mediated oxidations 
result in the formation of imino-quinone species which readily react with nucleophilic 
protein residues. In addition, UGT-mediated conjugation of diclofenac forms unstable 
acyl glucuronides. The ester bridge carbon exhibits electrophilic properties and 
attracts nucleophilic partners. Isomerization from the 1-O-β- to a 3-O-β-form can also 
give rise to electrophilic aldehydes that form covalent adducts with nucleophiles [51]. 
Accordingly, changes in genes encoding for the involved enzymes can decrease 
susceptibility towards DILI [69, 70]. Disposition of the major acyl glucuronide 
metabolite is mainly in the canalicular plasma membrane, mediated via active MDR2-
transport. Thus, decreased transporter activity also reduces the risk for DILI [70]. In 
addition, diclofenac metabolites were shown to decrease the cellular ATP content [71, 
72] and to impair mitochondrial function via respiration uncoupling after disruption of 
the proton gradient [73]. Furthermore, oxidative stress has been described as risk 
factor, originating from the activation of the antioxidant response pathway by 
diclofenac metabolites [74, 75]. Imino-quinone-like intermediates are also prone to 
undergo redox cycling and potentiate the pro-oxidant state [76]. Besides, in some 
patients hypersensitivity symptoms were observed and IgM antibodies were identified, 
reactive against erythrocytes only in presence of 4’-hydroxydiclofenac acyl 
glucuronide [77]. This provides evidence for involvement of the immune system and 
may offer an explanation for the diverging safety pattern in patients. However, no 
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genetic polymorphisms or underlying disease could be clearly correlated with 
increased risk for diclofenac-induced hepatotoxicity [73]. 
 
 
 
Figure 1.5: Metabolic pathways of diclofenac and their functional consequence 
 
 
Troglitazone 
Troglitazone (TGZ) was the first peroxisome proliferator-activated receptor gamma 
(PPARγ) agonist from the thiazolidinedione group in use for treatment of type II 
diabetes [78]. However, the FDA decided to withdraw TGZ from the market in 2000 
due to high incidence of reports hepatotoxicity [79, 80]. 
After numerous studies, several factors contributing to hepatotoxicity have been found 
(see Figure 1.6). Two structural moieties of TGZ undergo CYP-mediated bioactivation: 
The chromane moiety can be oxidized to an electrophilic quinone-methide 
intermediate prone to react with nucleophilic acceptors [81]. Besides, the 
thiazolidinedione residue can undergo S-oxidation resulting in ring scission with 
increased electrophilicity. This feature is common within the group of structural 
analogue glitazone drugs. Rosiglitazone (RGZ) and pioglitazone (PGZ) were also 
found to form GSH conjugates, but are generally considered as safe [82]. One reason 
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may be the cytotoxicity caused by TGZ but not RGZ and PGZ in humans [83]. In 
addition, the parent TGZ and its major sulfate metabolite are related to cholestasis. 
Both species were found to inhibit the bile salt export pump (BSEP) in rat and human 
[84, 85]. The resulting intracellular accumulation of bile salts causes mitochondrial 
toxicity and a loss of membrane potential [86, 87]. Remarkably, RGZ and PGZ 
possess a similar potential to inhibit BSEP [88]. 
Summarizing these effects, it can be concluded that hepatotoxicity is related to the 
TGZ-unique chromane moiety which may, as additional risk factor, induce oxidative 
stress via redox cycling of the quinone metabolite. Furthermore, the higher dosage as 
compared to RGZ and PGZ may provoke the manifestation of effects like BSEP 
inhibition into cholestasis. 
 
 
Figure 1.6: Selected metabolic pathways of troglitazone and functional consequence 
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1.4 Tools for investigation of metabolism and drug safety 
1.4.1 Hepatic in vitro systems for drug metabolism 
To study pharmacokinetic and related safety questions, it is important to use test 
systems that can mimic the liver with respect to the needed functions, as it would be 
unethical to conduct early screening and safety studies in humans. Likewise animal 
experimentation should be applied only when reasonable to assure compliance to the 
3R principle of replacement, reduction and refinement in animal testing. Interspecies 
differences are another reason for waiving them. Thus, several in vitro model systems 
are employed to provide information on selected pathways with different abilities to 
reflect hepatic function. 
Cellular systems 
The gold standard for metabolism studies are primary hepatocytes. They provide a 
realistic image of hepatic biotransformation because all relevant drug-metabolizing 
enzymes are present and also influence of active and passive transport on cellular 
drug uptake can be studied. Additionally, changes in gene expression e.g. via enzyme 
induction can be detected with RNA profiling, protein quantification or functional 
assays. Metabolism-induced and direct cytotoxicity can be assessed and enables DILI 
studies. However, cells from different donors may show large interindividual 
differences such as in activity of polymorphic enzymes. Moreover, access to human 
tissue is limited and handling and storage with retained viability is laborious. To cope 
with these problems, techniques like stem cell-derived hepatocytes or tumor derived 
cell lines have been emerging in the last years. They can be used for specific questions 
but are not valid to replace functional, mature hepatocytes yet. 
Subcellular fractions 
Liver microsomes (LM) are the most popular system to investigate hepatic metabolism. 
These artificial vesicles from the endoplasmatic reticulum comprise mainly CYP 
enzymes, FMOs and UGTs. They can be prepared easily and pooling of many donors 
can provide a representative enzyme pattern. Long-time storage without activity loss 
is possible which facilitates handling and enables high throughput-based applications. 
However, limitations are the lack of cofactors, which must be added separately to start 
the enzymatic reaction. Also the enzyme abundance does not represent the in vivo 
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situation and may result in overestimation of oxidative pathways. Another subcellular 
model for metabolism studies is the S9 fraction. This is the supernatant after 
centrifugation of cell homogenate at 9000g and is comprised by the microsomal and 
cytosolic fraction. Hence, as compared to LM, it additionally contains sulfotransferases, 
GSTs, xanthine oxidases (XO), aldehyde dehydrogenases (ADH) and NATs. 
Both systems are employed for kinetic and metabolic profiling of a drug, but mainly for 
inhibition studies in the context of drug-drug interactions. 
Recombinant enzymes 
The simplest method to study selected metabolic pathways is by using single drug 
metabolizing enzymes, e.g. CYPs. They can be generated recombinantly in host 
organisms like yeast, E. coli or other bacterial cell lines. Often co-expressed with P450 
oxidoreductase they are employed for reaction phenotyping, drug-drug interaction 
studies (enzyme inhibition) and specialized mechanistic questions. Due to the high 
concentration of CYPs as compared to other metabolic systems, recombinant 
enzymes are valuable to study metabolism of stable compounds. However, a full 
metabolic pattern cannot be deducted and only some specific enzymes are available. 
To compare results with microsomal activities, correction factors must to be integrated. 
 
1.4.2 Reactive metabolite assessment 
Reactive metabolite formation has been generally accepted as one major contributing 
factor to DILI. Thus, minimization of human exposure to reactive metabolites is 
desirable and should be controlled by identification of metabolic soft spots early in 
drug discovery [6]. 
As electrophilic metabolites have a short lifespan, it is more appropriate to monitor 
stable reaction products with nucleophilic acceptors. The most reliable way to detect 
and quantity reactive metabolites is via determination of covalent binding of 
14C-radiolabeled compound to cellular proteins in in vitro metabolism systems such as 
hepatocytes or microsomes. After removal of free compound, the protein bound 
radioactivity can be easily quantified by e.g. scintillation counting. However, synthesis 
of radiolabeled compound is laborious and thus expensive. Therefore, assays using 
cold substrate have emerged as well. Most reactive intermediates can be trapped as 
sulfur-adducts with the soft nucleophilic scavenger GSH. Detection of GSH conjugates 
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is routinely done with mass spectrometry which allows for untargeted analysis [89, 90]. 
However, hard electrophiles such as iminium-containing intermediates do not form 
stable adducts with GSH. They can be trapped using 14C-labeled cyanide as trapping 
agent and are quantified over radioactivity counting [91]. Also, other preclinical 
screening assays such as enzyme inhibition assays can give information on binding 
of reactive species to functional proteins. Time-dependent inhibition of CYP enzymes 
indicates irreversible conjugation of parent or metabolite to the active or an allosteric 
site of the enzyme. 
 
1.4.3 Investigation of cellular oxidative stress and related toxicity 
Consequences of oxidative stress can be examined on different levels within the cell. 
These are adaptation of cell homeostasis as a response to oxidative stress, specific 
damage of cell organelles, or cytotoxicity, all providing different types of information.  
To monitor cellular adaptation towards pro-oxidant states, it is beneficial to observe 
effects related to the antioxidant response pathway. For example, the increased 
transcription of genes encoding for cytoprotective proteins manifests in elevated 
mRNA levels. Activity determination of dependent antioxidant enzymes (e.g. SOD, 
GSH peroxidase, and catalase) or agents (e.g. ascorbate, tocopherol) may serve as 
complementary markers. Most frequently GSH depletion or dimerization is used as 
analytical marker [92]. These adaptive processes indicate alterations in the cellular 
health state, also transient or prolonged ones, early before overt damage occurs. 
However, it may be difficult to decide whether changes are physiological or will result 
in pathological effects. 
Another strategy is the detection of modified end-products that do not occur 
physiologically, such as carbonylation of amino acid residues due to protein oxidation 
or 8-hydroxy-2’-deoxyguanosine formation due to DNA oxidation. Lipid peroxidation 
can be determined via conjugates of specifically formed aldehydes, malondialdehyde 
and 4-hydroxynonenal, both cleavage products of peroxidized polyunsaturated fatty 
acids. Peroxidation of arachidonic acid gives rise to isoprostanes, the cis-isomers to 
the prostaglandins. They are chemically stable and can be measured from different 
biological fluids noninvasively. These markers clearly indicate a pathophysiological 
excess of pro-oxidant species that the cell cannot balance anymore. Still, in some 
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cases this damage may be repaired whereas in others it may be persistent and result 
in cell toxicity. 
Finally, it is possible to monitor effects based on major functional impairment or even 
cell death, such as deficient ATP production or cell membrane leakage via 
extracellular occurrence of lactate dehydrogenase (LDH), or alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) in vivo. However, these markers can only 
reveal evident toxic effects and do not give insight on preceding mechanistic pathways. 
In summary all groups of markers are complementary and contribute to a 
comprehensive picture of mechanisms and outcomes of disturbance of cell 
homeostasis. 
 
1.4.4 DILI in drug development: Screening approaches 
The illustrated examples show that many aspects of idiosyncratic DILI remain unclear 
and that working hypotheses cannot be translated to all cases. Therefore, the 
perception of valuable safety assessment moved away from isolated evaluation of 
bioactivation towards the generation of differentiated mechanistic information on a 
drug’s toxicity risk as illustrated in Figure 1.7. Experience from drug discovery showed 
that the simplification ‘structural alert = bioactivation = toxicity’ does not apply, mainly 
because in vivo metabolism often differs from the detected in vitro pathways [93]. 
However, as reactive metabolite formation is the only accepted evidence in the 
development of DILI, use of this information as a starting point for risk assessment is 
reasonable. Recent approaches improved the safety prediction of absolute covalent 
binding data by normalizing to the dose [5, 31, 48, 94] or by estimation of a covalent 
binding body burden [3, 95]. Still, false positive and false negative results are 
remaining and consequently it was suggested to consider mechanistic effects on cell 
health state to characterize compounds reliably [7]. Thompson and coworkers applied 
this strategy by defining a panel of in vitro assays addressing cellular endpoints. 
Together with covalent binding data, these were then combined to an integrated in 
vitro hazard matrix which allowed for distinction of a safe and different hazard zones 
[96]. However, most development drug candidates possess at least some in vitro alerts 
that would translate into a hazard. Thus, an evaluation of in vivo risk would remain 
problematic for them. 
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In summary, recognition of the complexity of idiosyncratic toxicity in the last years 
resulted in the creation of integrated mitigation strategies which may compensate for 
incomplete mechanistic understanding of DILI. However, all attempts show that a 
comprehensive risk assessment is not possible from the existing in vitro tools yet. 
 
 
 
Figure 1.7. Changing understanding of reasonable safety assessment for DILI from 
covalent binding determination to an integrated mitigation strategy. 
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2 OBJECTIVE OF THE WORK 
This work was conducted to establish improved in vitro testing strategies to address 
risk factors for DILI in context with metabolic drug activation. Thus, the goal was a 
better differentiation between safe and DILI drugs. 
Bioactivation potential should be evaluated in combination with pharmacokinetic 
properties as surrogate for DILI risk. As complementary tool to current risk assessment, 
robust safety biomarkers from non-invasive sources should be identified and validated 
with DILI model compounds. The main focus was on investigation of oxidative stress. 
This compound-related risk factor for hepatotoxicity gives insight into cellular 
mechanisms and may also serve as markers for monitoring of patients. Overall, an 
extrapolation across species from rodent to human as well as from in vitro model 
systems to the in vivo situation should be established. 
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3 RESULTS AND DISCUSSION 
 
3.1 The value of bioactivation assessment for the prediction of DILI 
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Abstract 
Idiosyncratic drug-induced liver injury (DILI) is a major concern for pharmaceutical 
industry. Chemical reactive drug metabolites (RM) and subsequent covalent protein 
binding (CVB) are believed to contribute to mechanisms leading to DILI. Various 
efforts have been made in the past to proof or disproof the correlation between CVB 
properties, daily dose and other pharmacokinetic properties and a drug’s susceptibility 
to cause DILI. Most of the concepts including the ‘zone classification system’ 
previously established by Nakayama suffer from a high number of false positive 
correlations or equivocal classifications. Here, we examined a large set of 91 drugs 
with different history of DILI. An improved classification of DILI properties from 85 to 
94% correctly classified compounds was achieved by correcting CVB by intrinsic 
clearance. A further improvement to 97% correct classifications was achieved by 
substituting daily dose by the hepatic inlet concentration, determined by systematic 
concentration and absorption. As the intrinsic property of covalent binding alone does 
not correlate quantitatively with DILI risk, we propose to use microsomal glutathione 
(GSH) trapping as binary output and surrogate for CVB. A good correlation to high risk 
DILI drugs was evident, especially when integrating daily dose. Here, a sensitivity of 
78% and a specificity of 94% for correct classification were achieved. Even though 
GSH trapping may miss certain electrophiles and phase II bioactivation is not captured 
in microsomes, fewer false negative classifications were observed than by hepatocyte 
CVB. In contrast, the integration of drugs with intermediate risk for DILI (based on case 
reports) decreased the correlation significantly. This may be due to misleading 
classification but also to the fact that mechanisms independent from bioactivation are 
involved in development of DILI. 
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Introduction 
Idiosyncratic drug-induced liver injury (DILI) is a major concern for pharmaceutical 
industry as it occurs only rarely, but is often related to serious outcomes such as liver 
failure and death. Due to the low frequency and poor predictability in preclinical 
studies, DILI has led to late stage attrition or withdrawal of promising new medical 
treatments [1, 2]. Investigation of case examples of affected drugs led to the 
generation of different hypothesis for the development of DILI which suggest an 
involvement of chemical reactive metabolites. These may be able to exert covalent 
binding (CVB) to cellular macromolecules and damage their function, a process which 
is generally accepted as initializing or at least contributing mechanism to DILI. 
Therefore assessment of CVB properties of a drug is nowadays frequently conducted 
in drug discovery with the aim to reduce bioactivation to a minimum [3]. 
However, a growing body of evidence exists on the fact that CVB does not determine 
toxicity alone, including qualitative and quantitative aspects. Some drugs that exhibit 
CVB do not cause problems in clinics and some drugs that bind to proteins to a high 
extent exhibit less toxicity than others with a low degree of CVB. These findings 
suggest that additional risk factors must be involved in modulation of DILI response 
[4, 5]. 
The original approach of quantitative determination of CVB from microsomal matrix 
was able to detect hepatotoxins [6], however resulting in many false positive results 
due to the exaggerated ratio of bioactivation relative to detoxification pathways. 
Therefore, hepatocytes were then selected as more appropriate system which 
accounted for phase II conjugation reactions as alternative or detoxification pathways 
besides oxidative bioactivation. The gained quantitative improvement could still did not 
result in the avoidance of false correlations. It was therefore attempted to incorporate 
relevant pharmacokinetic parameters that could normalize the amount of in vitro CVB 
to its relevant equivalent in vivo. Bauman et al. used a ‘total body burden of CVB’ 
(calculated from total and CVB related intrinsic clearance together with the daily dose) 
as correction factor for absolute data to improve separation of hepatotoxins and non 
hepatotoxins [7]. The finding, that a relationship exists between daily dose and DILI 
[8] was also applied by Nakayama et al.. The authors established a ‘zone classification 
system’ for toxic versus safe drugs by multiplication of hepatocyte CVB data and daily 
dose as decision criteria [9]. Here, it was possible for the first time to cluster 
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compounds based on bioactivation properties. Based on this knowledge Satakis and 
coworkers designed a decision tree for continuation or termination of suspicious drug 
candidates using clinical dose and an ‘in vitro reactive metabolite assay signal’ [10]. 
As none of these approaches could avoid an overlap of toxic and non-toxic compounds 
with false positive and false negative outcomes, Thompson at al. defined an ‘in vitro 
hazard matrix’ comprised by a CVB burden together with cellular toxicity endpoints as 
additional risk factors for DILI [11]. With this approach the authors managed to 
eliminate false negative, but not false positive results. Although this approach 
eliminates the risk of moving potential DILI drugs into clinical development, this 
approach likewise is overly sensitive and may unduly eliminate potentially safe and 
efficacious new drugs. This shortcoming of most approaches applied to reactive 
metabolite characterization during drug discovery and early development has recently 
been summarized by a consortium of scientists from pharmaceutical industry and 
academia [12]. The considerations in this article that for the first time attempted to 
reflect a consensus on common strategy regarding reactive metabolite 
characterization proposes daily dose as critical input parameter to DILI risk. 
The rationale of the described strategies to incorporate dose or clearance was to more 
precisely and realistically estimate the drug’s exposure to the body, in particular the 
liver. Exposure is influenced by various factors from all pharmacokinetic phases which 
need to be considered for evaluation. Namely, the fraction absorbed, first-pass 
intestinal metabolism, systematic distribution, fraction of hepatic (first pass) 
metabolism and elimination modulate the total in vivo exposure. In this study, we 
evaluated the contribution of different input variables to the correct classification of 
DILI outcomes for a dataset of 91 drugs by statistical approaches. The aim was to 
numerically describe risk factors for DILI by incorporation of normalized daily dose 
(body burden) and other pharmacokinetic parameters in order to provide a numerical 
classification of critical parameters such as “high” and “low” dose. In vitro microsomal 
intrinsic clearance or the theoretical liver inlet concentration as correction factors were 
incorporated into CVB data to better classify DILI drugs. We used a comprehensive 
data set of 91 drugs with and without DILI history, having CVB data for 51 of them. For 
these compounds the relationship between CVB properties and daily dose as originally 
shown by Nakayama was applied and compared to the proposed new correlation 
models. To account for the supposed small impact of absolute CVB, the potential to 
replace quantitative CVB data by qualitative bioactivation data was investigated as 
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well. The ability of drugs to form stable glutathione (GSH)-drug conjugates was 
evaluated as binary output. 
In vitro data was generated in house and completed with data from literature. Clinical 
pharmacokinetic data was extracted from literature. It has to be noted that most of the 
chosen toxic compounds cause hepatotoxicity as adverse endpoint. However, also 
some drugs whose idiosyncrasy manifests in immune- or hemotoxicity were included. 
It is believed that underlying mechanisms are comparable or mediated via similar 
pathways. All results were investigated by ordinal logistic regression and confusion 
matrix evaluation as statistical tools. 
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Material and Methods 
Chemicals 
Williams’ medium E, dimethyl sulfoxide p.a., formic acid p.a., insulin, streptomycin, 
penicillin, hydrocortisone, glucose-6-phosphate disodium salt hydrate, β-nicotinamide 
adenine dinucleotide phosphate hydrate (NADP), were obtained from Sigma Aldrich 
(St. Louis, MO, USA). Glutamine, gentamycin were purchased from Life Technologies 
Invitrogen (Lucerne, Switzerland) and acetonitrile LC-MS grade from Fisher Scientific 
(Wohlen, Switzerland). Water of chromatography grade and magnesium dichloride 
(MgCl2) was obtained from Merck (Darmstadt, Germany). Radiolabeled and unlabeled 
compounds were synthesized in house. Human liver microsomes were purchased 
from BD Biosciences, Woburn, MA. 
 
CVB to human hepatocytes 
For 51 marketed compounds CVB data was received from different sources which 
were either from in house studies or published results (in house, n=11; Nakayama et 
al., n=33 [9]; Thompson et al., n=4 [11]; Bauman et al., n=2 [7]; Lévesque et al., n=1 
[13]) using a comparable experimental setup. For the in house experiment procedure 
was as follows: Human cryopreserved hepatocytes were thawed in accordance to the 
supplier’s protocol and diluted to a final concentration of 106 cells / ml in incubation 
medium. After 15 minutes of pre-incubation 10 µM 14C-radiolabeled compound was 
added and cells were kept at 37°C in a humidified atmosphere (5% CO2/95% air) for 
3 h. Incubation was stopped by precipitation with one volume of acetonitrile on a filter 
plate (Multiscreen deep well solvinert, Millipore). After 15 min of mixing, the plate was 
centrifuged at 20°C for 20 min at 1800g, collecting the filtrate into a deep well plate. 
The remaining precipitate was washed 8 times with MeOH/0.1%H2SO4, collecting the 
eluting wash solution in four portions by centrifugation for 3 min at 1500g. An aliquot 
of the filtrate and each wash step was transferred to labeled microscintilation plate 
(LumaPlate™-96, Perkin Elmer) and radioactivity measured on a scintillation counter 
(Topcount NXT HTS, Perkin Elmer) to determine recovery of radiolabeled compound 
and progress of the wash steps. 
The amount of CVB was calculated from the non-extractable radioactivity after 
solubilization of the denaturated protein with 0.1 M NaOH/1% SDS as determined by 
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β-scintillation counting (TriCarb 3100 TR, Packard) and colorimetric determination of 
the protein concentration, as shown in Equation 3.1.1. 
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GSH trapping assay 
Human liver microsomes at a concentration of 1 mg/mL were incubated with 20 µM 
compound in 0.1 M sodium phosphate buffer substituted with 1 mM NADPH and 5 mM 
GSH. After 60 minutes incubation time reaction was stopped by adding one volume 
acetonitrile Organic solvent was then evaporated under a stream of nitrogen. After 
centrifugation at 5000g at 4°C for 10 min samples were injected to the LC-MS system. 
 
LC-MS analysis of GSH trapping samples 
LC-MS/MS analysis were performed on a triple quadrupole mass spectrometer 
(QTRAP 4000, AB Sciex, Warrington, UK) interfaced with a Shimadzu high 
performance liquid chromatography system. Analytes evaporated sample were 
enriched and separated by on-line SPE coupled chromatography within 14 min. Mass 
spectrometric detection was executed in negative electrospray ionization mode using 
a precursor ion (PI) scan with dependent enhanced resolution (ER) and enhanced 
product ion (EPI) scan. This method was previously reported by others [14, 15]. 
 
Human liver microsomal stability assay 
Compounds were dissolved in DMSO to obtain a 4 mM stock solution which was 
further diluted in incubation medium for use in experiments. Microsomal incubation 
was prepared by supplementation of 0.1 M sodium phosphate buffer (pH 7.4) with 
3 mM glucose 6 phosphate, 0.5 mg/mL HLM, 3 mM MgCl2 and 10 µM of the respective 
compound. Incubation was started by addition of 1 mM NADPH and stopped after 1, 
3, 6, 9, 15, 25, 35, and 45 min by precipitation with three volumes acetonitrile 
containing internal standard. Samples were analyzed using LC-MS/MS (see there). 
Intrinsic clearance was calculated with the slope of the degradation curve as depicted 
in Equation 3.1.2 and 3.1.3. 
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LC-MS/MS analysis of in vitro stability samples 
The system consisted of a Shimadzu HPLC connected to a triple quadrupole tandem 
mass spectrometer (5500 QTRAP, AB Sciex, UK) equipped with either a XBridge 
phenyl column, 3.5 µm, 1.0 x 50 mm (Waters, Ireland) or with an Supelco Ascentis 
express C18 column, 2.7 µm, 2.1 x 20 mm (Sigma-Aldrich, St. Louis, MO). 
Two microliter sample were injected to the system and separated by gradient elution 
with mobile phase one consisting of water containing 0.5% formic acid/methanol 
(eluent A1; 95/5, v/v) and methanol (eluent B1) or mobile phase two consisting of water 
containing 20 mM ammonium bicarbonate/methanol (eluent A2; 95/5, v/v) and 
methanol (eluent B2). The gradient started with a total flow of 0.500 ml/min at 100% A 
which was kept for 0.07 min. Eluent B was then increased in a ballistic-shaped manner 
from 0% to 100% within 0.7 min. The flow was increased to 0.700 ml/min and the 
system flushed with 100% B for 0.18 min. From 0.91 to the end of the run at 1.4 min 
the system was re-equilibrated with 100% eluent A. MS detection was performed by 
selected reaction monitoring. Tuning parameters were defined for each analyte by the 
help of compound standards in positive or negative electrospray ionization mode 
depending on structural properties. 
 
Calculation of liver inlet concentration 
For the calculation of a theoretical liver inlet concentration ([I]in, Equation 3.1.4) the 
sum of the systematic average ([I]av, Equation 3.1.5) and the uptake to the liver was 
calculated considering the following parameters: logD at pH 6.0, polar surface area 
(PSA), absorption rate constant (ka, Equation 3.1.6), clearance after oral dose (CL/F), 
dose (D), dose interval (τ), fraction of dose reaching the portal vein (FDp=fraction 
absorbed x fraction escaping gut metabolism) and hepatic blood flow (Qh). 
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log L = 0.623 + 0.154 ∗ log TU.V − 0.007 ∗ YZ[ [16]  Eq. 3.1.6 
 
Lipohilicity was calculated with the following software tools: ClogP v4.94 program 
(BioByte Corp., Claremont, USA) for logP, Moloc (Gerber Molecular Design, Amden, 
Switzerland) for PSA and MoKa 1.1.0 (Molecular Discovery Ltd, Pinner Middlesex, 
UK) for pKa. The values used and the result can be found in Table A3.1.2. 
 
Statistical analysis 
Statistical determination of ordinal logistic regression for the correlation of different 
dependent variables was performed using the software Matlab 7.12. Equation 3.1.7 
describes the variables as follows: β are the coefficients of the regression and p the 
probability for a drug to be in one of the risk categories. Var1 and Var2 are the 
covariates that were correlated to generate a clustering of the compounds as shown 
in Table 1. The separation line between two risk categories was defined for the case 
the odds were unity as described by Nakayama el al., by application of Equation 3.1.8 
[9]. 
Dependent on the results of the ordinal logistic regression, sensitivity, specificity, 
positive (precision) and negative predictive value (NPV) were determined for the 
correct classification of DILI risk from a confusion matrix (Figure A3.1.1). Separation 
of low risk from risk and high risk drugs (condition A) was assessed and compared the 
separation in a reduced dataset containing low risk and high risk drugs (condition B). 
A similar approach was applied to validate the quality of the different correlation 
approaches after incorporation of pharmacokinetic parameters and substitution of 
CVB data by reactive metabolite formation (GSH trapping). 
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Table 3.1.1: Definition of covariates used for ordinal logistic regression analysis. 
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Var1 Var2 
Model 1 
(Nakayama) Daily dose CVB_heps 
Model 2 
(this work) Daily dose CVB_heps /CLint 
Model 3 
(this work) 
Liver inlet 
concentration CVB_heps 
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Results 
Experiment design 
Ninety-one model compounds were classified based on their history of safe use or 
development of DILI (Table A3.1.1). Compounds were classified in three categories 
with respect to their safety profile as previously reported [17]. Drugs withdrawn from 
the market or carrying a hepatotoxicity-related label were classified as ‘high risk’ drugs, 
substances with known history of liver injury were assigned as ‘risk’ drugs and those 
without increased incidence for liver damage were marked as ‘low risk’. For all drugs 
intrinsic clearance determination and GSH trapping assay was performed in 
microsomes or taken from the literature [18-20]. Oral plasma clearance data and other 
pharmacokinetic properties were extracted from literature (Table A3.1.2). For a subset 
of 51 compounds quantitative CVB data was collected (in house and literature results 
as described in Material and Methods, Table A3.1.1) and a theoretical portal vein 
concentration (‘liver inlet’) was calculated (Table A3.1.2). A quantitative evaluation of 
the different approaches for classification of DILI based on selected input variables 
results was conducted after ordinal logistic regression and further determination of 
descriptors for predictive values based on a confusion matrix approach. 
 
Statistical evaluation of variables describing DILI classification 
The present study was designed with the goal to evaluate the most sensitive variables 
for DILI classification based on drug bioactivation propensities and generic 
pharmacokinetic properties. Inspection of parameters of the present data set revealed 
that none of the used parameters was able to predict DILI in isolation. Means of CVB 
and clearance data did not show any obvious trend and possessed a wide standard 
deviation. This observation was also confirmed by a partial least squares discriminant 
analysis (PLA-DA) of the variables: The highest contributing value to separate the 
different classes was seen for dose and hepatic inlet concentration which are closely 
related (see Equation 3.1.5) with a trend towards a connection of high dose and high 
risk. Clearance was classified as minor determinant and covalent binding as important 
contribution factor, however not significant for one group (Figure 3.1.3). 
In order to investigate a potential improvement of the prediction of hepatotoxicity 
based on drug bioactivation, we build on the established zone classification system by 
Nakayama and coworkers [9]. This approach utilized hepatocyte covalent binding 
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(CVBhep) and daily dose as variables to classify drugs with different DILI properties. 
We used this approach as reference model that we further developed by modifying the 
input variables to two dependent models. An overview of the outcome is displayed in 
Table 1. As reference, model 1 corresponds to the original Nakayama model with an 
extended dataset, model 2 uses intrinsic clearance normalized covalent binding 
(CVB/CLint) and dose as determinants and model 3 employed covalent binding in 
combination with the hepatic inlet concentration as covariates. 
 
Quantitative CVB properties as prediction factor for DILI 
Inspection of individual input variable of the present data set revealed that none of the 
used parameters was able to predict DILI when applied in isolation. Means of CVB 
and clearance data did not show any obvious trend and possessed a wide standard 
deviation. This observation was also emphasized by a partial least squares 
discriminant analysis (PLA-DA) of the variables: The highest contributing value on 
separation of different classes of DILI was evident for dose and hepatic inlet 
concentration which are closely related (see Equation 3.1.5). These parameters 
revealed a trend towards the correlation of “high dose” with “high risk”. Clearance was 
classified as minor determinant and covalent binding as important contribution factor, 
however not statistically significant for one group. 
However, a combination of different parameters that previously had been argued to 
determine the classification of DILI resulted in distinct clusters for the different 
categories of DILI drugs. The results are graphically displayed in Figure 3.1.1. This 
classification was largely confounded when the entire dataset of compounds (n=51) 
was analyzed including those compounds classified as “risk” (Figure 3.1.1, left). 
Reducing the compound set to those compounds that were classified as “low risk” and 
“high risk” (n=33) a significantly better separation of both groups was achieved 
(Figure 3.1.2, right). Visual inspection of the data suggests an improved classification 
of DILI drugs when comparing to the reference model 1 to the most comprehensive 
approach in model 3. This included pharmacokinetic parameters and physico-
chemical properties of drugs that were used to derive a liver inlet concentration. A cut-
off line to separate safe from high risk drugs could be calculated by ordinal logistic 
regression with only one false positive classification (#42, gemfibrozil). 
A quantitative summary of the descriptive values of the different models is shown in 
Table 3.1.2. It was retrieved using a confusion matrix with the cut-off lines calculated 
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from the regression analysis for the three models. The values emphasize the 
differences in correct prediction for low risk (safe) versus risk and high risk drugs 
(condition A) and the reduced data set (low risk vs. high risk, condition B). The 
percentage of correctly classified compounds in average is 14% better for condition B 
as compared to condition A. For condition B an improvement for all parameters for 
model 3 as compared to model 2 and for model 2 as compared to model 1 indicates 
that the inclusion of clearance and liver inlet data results in an overall better 
predictivity. For condition A that attempt to classify safe drugs relative to risk and high 
risk drugs, an improvement for the most complex correlation of model 3 was not 
observed. Here, specificity and precision increased slightly whereas sensitivity and 
NPV decreased. 
 
Reactive metabolite formation as prediction factor for DILI 
We further investigated the substitution of CVB data by the qualitative potential of 
reactive metabolite formation as indicated by trapping of reactive species with 
glutathione (GSH) that was available for a set of n=91 compounds. Therefore, the first 
step was to assess the overlap between results from CVB assessment and its potential 
surrogate GSH trapping. 
A positive outcome in CVB assessment was defined with a threshold of greater than 
10 pmol drug derived material bound per milligram of hepatocyte protein. This value 
is derived from historical background data. The same outcome in both assays for the 
chosen data was achieved for 35 of 51 compounds (positives and negatives). Only 4 
of the 19 ‘true’ positives are classified as safe, all of them being low dose drugs (0.035 
mg – 20 mg/d). On the other hand, 9 (of 16) of of the ‘true’ negative compounds do 
have DILI alerts, for them, the average dose was 1700 mg/d. One of them, zomepirac 
(#91), which is known to form instable acyl glucuronides, has been recently found 
positive in CVB assessment, however only with 19.8 pmol/mg after 4 h of incubation 
[11]. With respect to the deviating results, the predicitvity of GSH adducts seems to be 
better as compared to CVB. 90% of the compounds with GSH alert and without CVB 
alert are classified as DILI drugs. Here, the oxidative activation seems to be the 
bioactivation pathway involved in reactive metabolite formation. This may not be 
captured in hepatocytes due to lack of dynamic range in hepatocyte CVB studies. The 
amount of toxic compounds in the false negative section, in contrast, is only 50%. 
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The correlation between CVB and body burden was further confirmed by substitution 
of quantitative CVB with GSH adduct formation which was done for a largely expanded 
data set (n=91 vs n=51 for CVB properties). 
Here, GSH adduct formation as qualitative outcome succeeded in classifying 64% of 
all compounds correctly for condition A (n=91 compounds). For the reduced data set 
(condition B eliminating the intermediate DILI risk category, n=54 compounds) even 
70% true results were obtained The sensitivity of the assay for condition B was at 77% 
suggesting that only 4 out of 18 DILI drugs were not correctly classified (Figure 3.1.2, 
bottom). Three of those four drugs were high dose drugs. E.g. ritonavir does form 
reactive metabolites which directly bind to the active side of the involved enzyme, 
namely CYP3A4 and are not able to diffuse away from the binding pocket. The 
precision of 55% reveals that the GSH experiment is over-sensitive (Figure 3.1.2, top). 
10 over 36 low risk drugs possess the potential to from RM. However, one of them 
was the aforementioned drug gemfibrozil (#42) whose classification may have to be 
reviewed. The other compounds were low dose drugs with an average dose of 28 mg 
per day. 
In general, the majority (76%) of high risk compounds given at > 100 mg per day 
possess a GSH flag, however, only the minority (15%) of low risk compounds given at 
> 100 mg per day do so. Low risk drug with a dose of < 100 mg per day had 35% GSH 
trapping positive results. One example is Ethinylestradiol (#35). Its ethinyl moiety is 
prone to form reactive metabolites, however as the daily dose is only 0.035 mg, the 
exposure to the reactive metabolite is not sufficient to cause toxicity. 
Based on these findings the daily dose was integrated as secondary criteria for risk 
assessment via GSH trapping. Applying this definition for the 54 safe and high risk 
drugs resulted in a vast improvement of prediction power (Figure 3.1.3). With only 4 
false negative and 2 false positive results (11%) a sensitivity of 78%, a specificity of 
94%, a precision of 88% and an NPV of 89% were achieved. 
Integration of the intermediate DILI risk category also revealed a substantial reduction 
of false positive results, i.e. a relevant reduction of over-exclusion of compounds. 
However, in parallel, the number of false negatives is increasing. Judging GSH adduct 
formation or a high dose as positive outcome leads to the invert effect: Whereas false 
positives are increased, the number of false negative results is reduced which is 
equivalent with an increase in sensitivity. In addition to the dose correlation a slight 
trend could be seen for high risk compounds that did not have a GSH trapping alert 
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when incorporating plasma clearance. Low clearance drugs may be underestimated 
in their CVB risk from short-period in vitro assays if bioactivation processes are 
quantitatively too slow. 
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Figure 3.1.1: Correlation of different variables for a zone classification of compounds 
of different classes of DILI properties as separated after linear logistic regression. 
Drugs with a low risk ( ), risk ( ) or high risk ( ) were clustered using the established 
Nakayama model (CVB in hepatocytes and daily dose) [model 1] or intrinsic clearance 
normalized CVB and daily dose [model 2] or CVB and hepatic inlet concentration 
[model 3]. Condition A (left) used three groups to DILI outcome (high risk, risk, low risk 
drugs) and condition B used a reduced data set (high risk, low risk drugs). 
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Figure 3.1.2: Reactive metabolite formation as results from GSH trapping (alert on top 
and absence of alert on bottom) in relation to daily dose and DILI category. 
 
 
 
 
 
Figure 3.1.3 Correlation plot for 
different variables for toxicity prediction. 
Height of the column corresponds to the 
amount of contribution. Standards 
deviations ranging from positive to 
negative indicate the absence of a 
significant trend within one of the tested 
groups. 
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Table 3.1.2: Predictive value of the different correlation models as determined after 
ordinal logistic regression and confusion matrix evaluation. Condition A (top) refers to 
the comparison of the group of the low risk compounds against risk and high risk and 
the condition (B) (bottom) to the comparison of low risk drugs against high risk 
compounds. 
    Sensitivity Specificity Precision NPV Correct 
       
Condition A  
(low risk vs. 
risk, high risk) 
Model 1 85% 71% 85% 71% 80% 
Model 2 82% 59% 80% 63% 75% 
Model 3 85% 65% 83% 69% 78% 
  
            
 
      
Condition B 
(low risk vs. 
high risk) 
Model 1 88% 82% 82% 88% 85% 
Model 2 94% 94% 94% 94% 94% 
Model 3 100% 94% 94% 100% 97% 
  
            
 
 
 
Table 3.1.3: GSH adduct formation as prediction factor for DILI. A GSH alert in 
combination with a daily dose higher than 100 mg was judged as positive outcome to 
predict the classification of high dose and low risk drugs. 
   Risk for DILI   
   n=54 high low   
GSH alert at 
> 100 mg  
yes 14 2 88% 
no 4 34 89% 
    78% 94% 89% 
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Discussion 
CVB as prediction factor for toxicity 
Although it is a generally accepted hypothesis that excessive covalent binding or 
critical covalent binding to sensitive cellular target proteins is related to development 
of toxicity, the quantitative relationship between both remains vague. Several groups 
have demonstrated the progress and limitations of a quantitative risk assessment 
based on covalent binding data over the last couple of years. The major shortcoming 
of several models was a remaining amount of false classified compounds. A reason 
may be the lack of mechanistic parameters in these analyses. Complex secondary 
mechanisms cannot be captured in vitro such as binding of reactive metabolites to 
physiologically sensitive proteins or the formation of neo-antigens triggering immune 
response only in certain cases. Therefore the susceptibility of individual patients 
remains elusive. In contrast to previous studies we applied a global inspection of a 
large dataset consisting of in house and collected literature data. We applied statistical 
analysis to describe the obtained results and compared different scenarios, namely 
the whole data set and a reduced set consisting of safe and high risk drugs. 
Using these prerequisites, the aim of this study was to review the relevance of covalent 
binding properties of compounds relative to their administered dose, systemic 
clearance and liver burden over time. It was presumed that a rapidly metabolized 
compound would not interact with a potential target in the same manner as a slowly 
activated compound. Therefore, bioactivation data was corrected for experimental 
(intrinsic) clearance. However, as integration of CLint data does only add value for 
drugs with an at least moderate turnover in vitro, oral plasma clearance data from 
clinical trials is needed for more meaningful information. As most comprehensive 
parameter for a drug’s potential to (adversely) interact with the liver the portal vein 
concentration was deemed. The applied calculation (see Equation 3.1.4) was 
comprised by two main components, the systematic average concentration and the 
absorption. Here, physicochemical properties and clinical pharmacokinetic data were 
integrated. 
Correlation of the present, extended data set (n=51) using the well accepted 
Nakayama-model (model 1) showed a comparable zone classification as described 
[9]. Normalization of the absolute CVB for the intrinsic clearance (model 2) and 
transformation of the maximum daily dose to a theoretical liver inlet concentration of 
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the (model 3) resulted in an improvement of predictability for low risk and high risk 
drugs. Here, sensitivity, selectivity, precision and NPV were increased by 9% from 
model 1 to 2, and by additional 3% for model 3. 
An improvement was seen namely for drugs where the primary input variable biased 
the classification in model 1. Acetyl salicylic acid [ASS] (#2) and rimonabant (#68) are 
generally considered as safe but exhibit a high dose (up to 2 g for ASS) and absolute 
CVB (1114 pmol/mg for rimonabant). On the other side benzbromarone (#12) and 
nevirapine (#53) are toxic drugs that show relatively low CVB in hepatocytes (12.1 and 
2.9 pmol/mg) and were therefore judged as safe. However, integration of in vivo 
clearance and bioavailability over the liver inlet concentration resulted in an adjustment 
to the correct area. The only false clustered compound in the latter model was 
gemfibrozil (#42) ranging as low risk compound in the hepatotoxic area. Although 
gemfibrozil is generally considered as relatively safe, reports on cholestatic events 
upon drug intake have been reported [21]. Besides, occurrence of myotoxicity is 
reported to be elevated, especially in combination with statins [22, 23]. The reason 
that the present study revealed benefit from incorporation of pharmacokinetic 
parameters which was not seen in a comparable extent in previous works as 
conducted by Bauman et al [7] may be due to the selection of extreme case examples 
(by excluding of the intermediate risk category for analysis) which however still 
represented a substantially larger data set (n=33 vs. n=18). This enabled the detection 
of general trends that may not apply for every individual drug. 
Nonetheless, integration of the ‘risk’ drug class as unacceptable group did not result 
into an improved prediction for the complex models. A positive change in one quality 
parameter was accompanied by a negative change in another one, resulting in an 
overall similar prediction power that did not improve (see Table 3.1.3, lower part). The 
reason for these findings can be understood when inspecting the applied statistical 
model (PLS-DA). Dose and CVB were identified as most contributing variables for the 
separation of the different classes. Figure 3.1.3 emphasizes that CVB alone is not 
indicative for DILI classification. The most important factor for the calculated liver inlet 
concentration is the dose; the impact of both variables is comparable. For a 
comprehensive comparison of the models it has to be considered also, that data 
collection is much more complicated for in vivo parameters as used in model 3. For 
safety and monetary reasons the aim of industry and authorities is to learn about 
potential adverse reactions as early as possible, at a point where pharmacokinetic 
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data are rarely available. Substitution of clinical data by physiology-based 
pharmacokinetic modeling displays a source of ambiguity. 
The constant prediction power may originate from the uncertainty in extracted and 
calculated results. As data on the fraction absorbed (Fa) is rarely accessible, mostly 
oral bioavailability (Foral) was used as parameter. In cases where no value was 
available, 1.0 (equivalent to 100%) was assumed. However, the difference between 
Fa and Foral can be crucial if the compound possesses a high first pass (gut and liver) 
metabolism. In these cases, the fraction absorbed would be underestimated by Foral. 
In addition to the included parameters, knowledge on the fraction metabolized (fm) as 
opposed to renal or biliary excretion of unchanged drug is crucial [24]. Only if the 
amount of hepatic metabolism equals 1 (i.e. 100% of the elimination of the compound 
is via metabolism) the in vitro bioactivation is comparable to the in vivo situation. 
The case of gemfibrozil illustrates a bottleneck of the compound classification. For 
very toxic or extremely well-tolerated substances (here: high risk and low risk) the DILI 
history is very clear. However, several drugs possess case reports of hepatic 
alterations and for most of them an exclusion of other causalities such as co-
medication or underlying disease is rarely possible. This may lead to false positive 
conclusions [25]. On the other hand, DILI is also believed to be underreported because 
of insufficient pharmacovigilance systems or awareness of the causative context [26]. 
Strategies for the handling of DILI cases by the authorities may also deviate depending 
on indication of the drug, medication alternatives or class effects. It is therefore a 
primary challenge to rate the ‘true’ safety profile of a drug. 
 
GSH adduct formation as prediction factor for toxicity 
Analyses of the present and previously reported data indicate a limited impact of 
quantitative covalent binding in human hepatocytes and their narrow dynamic range 
(a background of approx. 2 pmol/mg up to 100 pmol/mg for high-binding compounds). 
It was therefore hypothesized that assessing bioactivation in a binary yes/no manner 
by GSH adduct formation may be sufficient for reliable evaluation. 
Previous studies showed that the amount of GSH adducts and the amount of covalent 
binding are not correlated. It was suggested recently that this is due to the differences 
in reactivity of glutathione and microsomal protein, as well as the deficiency of 
glutathione to trap hard electrophiles and the differences in life time and partition 
(aqueous/protein) of RMs [27]. However, conduction of GSH trapping is much simpler 
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and does not require radiolabeling of compounds. Therefore, GSH trapping assays 
are frequently incorporated into preclinical risk assessment strategies. GSH adduct 
formation, mainly in combination with CYP mechanism-based inhibition data can serve 
as indicator for the risk of hepatotoxicity and substitute CVB data [10, 17]. Likewise, 
we found a correlation between GSH adduct formation and toxicity which was 
improved after integration of dose, as it was proposed recently [28]. Only a small 
amount of false positive as well as negative results were retrieved when 100 mg daily 
dose was added as criterion (Table 3). This correction may account for detoxification 
mechanisms that are depleted at higher drug doses. 
As GSH trapping is routinely conducted in liver microsomes and hepatocytes are 
considered as gold standard for covalent binding assessment, potential differences in 
outcome of the assays may be also due to the metabolic system. To exclude this bias 
the correlation of covalent binding data in microsomes and hepatocytes of the present 
data set were confirmed (data not shown). A comparison of GSH and CVB assay 
showed a congruence of 69%. Detailed inspection of the results showed a higher 
failure for quantitative CVB evaluation in human hepatocytes to correctly classify 
toxicity as compared to GSH adduct formation. The majority of compounds with 
positive GSH trapping result and lack of significant CVB were indeed DILI drugs. The 
reason may be predominant activation via CYP enzymes in the present cases. CYPs 
are higher expressed in microsomes, which is the test system of the GSH trapping 
assay. The lower sensitivity and dynamic range of CVB determination in hepatocytes 
may result in failed recognition of CVB properties in that assay. Remarkably 47% of 
the compounds that tested negative for bioactivation by quantitative CVB and GSH 
trapping belong to the DILI classes (risk and high risk) drugs. This can be explained 
by the high clinical dose (average1400 mg/day) together with a low rate of 
bioactivation in vitro: The CLint values for the affected compounds range from 0 to 
19.2 mL/min/mg with a mean of 5.8 mL/min/mg and median of 2-5 mL/min/mg. 
Alternatively it is also likely that other, non bioactivation related mechanisms contribute 
to the observed toxicity of these molecules. 
 
 
Perspective for future risk assessment of DILI 
The central question of this research was to find better ways of classifying DILI 
properties for drug candidates. It is appreciated that this early classification is by no 
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means a predictive measure of DILI outcome in the clinical setting. Still the existing 
correlation between bioactivation, pharmacokinetic parameters including daily dose 
emphasizes that bioactivation may leads to a substantially increased DILI risk. This 
particularly holds true for cases where a certain dose threshold is exceeded. The 
comprehensive analysis of the set of 91 drugs with classified DILI properties suggests 
100 mg as a threshold dose for additional safety considerations. Considering the 
limited impact of the absolute amount of CVB, we suggest to non-quantitatively 
determine reactive metabolite formation by e.g. GSH trapping. In contrast, a better 
understanding of the drug exposure is of major importance as mitigation factor for DILI 
risk [29]. The integration of pharmacokinetic knowledge can support a reliable 
judgment of the outcome of a bioactivation assay. This may be not applicable for 
screening tasks, however, this tool may confirm the decision on whether to terminate 
or continue drug development for individual cases. 
Another strategy for a better understanding of the relationship between protein 
covalent binding and toxicity outcomes is the detailed analysis of protein targets of 
reactive metabolites. It is hypothesized that the specific modification of critical protein 
targets and not the total unspecific covalent binding in general determines the risk for 
toxicity. 
For a consolidated evaluation of this hypothesis a reactive metabolite target protein 
database has been created by Hanzlik and coworkers. Their goal was to provide a 
listing of known RM targets to enable the identification of general protein patterns that 
determine toxicity [30]. However, until now database entries are mainly available for 
chemicals. Additionally, association of protein bands on a gel do not necessarily reflect 
that these proteins were covalently modified until the protein modification has been 
unequivocally demonstrated on a peptide or amino acid level. The identification of 
peptide targets from functional enzymes was reported for a model compound known 
to induce high CVB to rat and human hepatic tissue by application of a targeted 
proteomics approach [31]. However, detection of protein targets can be challenging 
when the absolute covalent binding is low or the abundance of the target is minute 
relative to a large excess of unmodified proteins. A comprehensive correlation of 
protein targets and DILI impact will be revealed in the future when more proteomic 
data is available. 
Besides the limitations of existing RM assessment tools, one must also be aware that 
bioactivation is almost never the only determinant for drug-induced hepatotoxicity. 
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Heterogeneous mechanisms are involved in its development and do not allow the 
prediction via one single approach. Thus, for a significant improvement of safety 
assessment causalities have to be understood in detail and translated into 
investigation models and biomarkers [12]. These may then replace or complement the 
need of integrating bioactivation findings in a proper context [32]. 
In summary, the current knowledge advises to design potent, selective and therefore 
low dose drugs with moderate turnover and minimal undesired bioactivation. For drug 
candidates that are deficient of some of the desired properties, the presented 
assessment tools can support the rating of these compounds and the selection of the 
best among a series of related compounds. It may be necessary to embark on detailed 
assessment of secondary toxicity endpoints as potential contributing factors in order 
to estimate the DILI risk for a predicted dose range in case a DILI risk cannot be 
excluded. 
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Appendix 
 
  
Condition 
  
  
positive negative 
  
Test 
+ true positive (TP) false positive (FP) Precision TP/TP+FP 
- false negative (FN) true negative (TN) NPV TN/TN+FN- 
  
Sensitivity specificity 
  
  TP/ TP+FN TN/ TN+FP  
 
 
 
Figure A3.1.1: Definition of a confusion matrix with output parameters to evaluate the 
qualitative outcome of an individual experimental set-up. 
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Table A3.1.1: Experimental data for low risk drugs 
 
index name 
 daily 
dose 
 [mg] 
RM alert by 
GSH 
trapping 
CLint_HLM* 
[mL/min/mg] 
CVB_heps 
[pmol/106 
cells] 
Source 
CVB 
2 Acetyl salicylic acid 2000 no 10.0 0.4 int. 
4 Amantadine 600 no 3.0 nd  
7 Amlodipine 10 no  5.6 13.3 [9] 
9 Aripiprazole 30 yes 5.0 nd  
11 Baclofen 10 no [0.1] nd  
14 Buspirone 30 yes 19.0 nd  
15 Caffeine 900 no 4.0 0.2 [9] 
26 Dextromethorphan 180 no 16.0 nd  
31 Donepezil 10 yes 2.0 13.5 [9] 
33 Enalapril 20 no 2.0 nd  
35 Ethinylestradiol 0.035 yes 32.0 80.6 [9] 
41 Gabapentin 2400 no 8.5 nd  
42 Gemfibrozil 900 yes 12.0 8.4 int. 
47 Levofloxacin 750 no [0.1] 0.1 [9] 
48 Lidocaine 105 yes 6.0 2.2 int. 
49 Lisinopril 20 no 2.8 nd  
50 Lorazepam 3 no 2.0 nd  
51 Memantine 30 no [0.1] nd  
54 Nifedipine 60 yes 7.0 nd  
55 Olanzapine 20 yes [0.1] 43.8 [11] 
56 Olmesartan 40 no 38.0 1.4 [9] 
57 Paroxetine 40 yes 6.0 nd  
58 Pentobarbital 100 no 6.0 nd  
60 Pindolol 15 yes [0.1] nd  
61 Pioglitazone 45 no 7.0 31.9 [11] 
62 Pravastatin 80 yes 4.0 2.5 [9] 
68 Rimonabant 20 no 10.0 1114.8 [11] 
71 Rosiglitazone 8 yes 6.0 42.5 [9] 
72 Sertraline 50 no 5.0 nd  
74 Sitagliptin 100 yes [0.1] nd  
76 Sumatriptan 100 no 11.4 nd  
81 Tocopherol acetate 20 no 24.0 1.2 int. 
85 Valsartan 320 no 2.0 0.4 [9] 
86 Venlafaxine 150 no [0.1] nd  
88 Warfarin 15 no [0.1] 8 [9] 
90 Zolpidem 20 no 6.0 nd int. 
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Table A3.1.1 contd: risk drugs 
 
index name 
 daily 
dose 
[mg] 
RM alert 
by GSH 
trapping 
CLint_HLM* 
[mL/min/mg] 
CVB_heps 
[pmol/106 
cells] 
Source 
CVB 
1 Acetaminophen 4000 yes [0.1] 8.4 [9] 
3 Alprazolam 1.5 no 3.0 nd  
6 Amitriptyline 150 no 6.0 nd  
10 Atorvastatin 80 no 15.0 209.2 [9] 
16 Captopril 75 yes [0.1] nd  
18 Carvedilol 25 yes 8.0 nd  
19 Celecoxib 400 no 15.0 7.1 [9] 
20 Chlorpromazine 500 yes 7.0 nd  
22 Citalopram 40 no 3.0 nd  
23 Clopidogrel 75 yes 513.0 75 [9] 
25 Desipramine 150 yes 5.0 nd  
27 Diazepam 15 yes 7.0 0.1 [33]  
28 Diclofenac 200 yes 68.0 65.8 int. 
29 Diltiazem 180 no 5.0 nd  
30 Diphenhydramin 300 no 5.0 0.1 [7] 
32 Duloxetine 20 yes 37.9 nd  
34 Erythromycin 1000 no 3.0 nd  
36 Felbamate 3000 no [0.1] 0.1 [7] 
37 Fenofibrate 300 no 515.4 nd  
38 Fluoxetine 20 yes 6.0 9 [9] 
40 Furosemide 80 no 2.0 nd  
43 Haloperidol 10 yes 4.0 nd  
45 Imipramine 300 yes 6.0 15.5 [9] 
46 Indomethacin 200 yes 4.0 32.9 int. 
59 Phenytoin 600 no 2.0 3.7 [9] 
63 Prazosin 4 yes 5.0 nd  
64 Procainamide 4000 yes 8.0 nd  
65 Propranolol 480 yes 4.0 9.4 [9] 
66 Quetiapine 600 yes 11.0 nd  
67 Ranitidine 300 no [0.1] nd  
69 Risperidone 6 yes 6.0 nd  
73 Simvastatin 20 no 124.0 nd  
75 Sulfamethoxazole 1600 no [0.1] 0.8 [9] 
77 Tacrine 160 yes 2.0 5.4 [9] 
78 Tamoxifen 40 yes [0.1] 64.9 [9] 
87 Verapamil 480 yes 5.0 16 [9] 
89 Zafirlukast 40 no 16.0 19.1 [9] 
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Table A3.1.1 contd: high risk drugs 
 
index name 
 daily 
dose 
[mg] 
RM alert by 
GSH 
trapping 
CLint_HLM* 
[mL/min/mg] 
CVB_heps 
[pmol/106 
cells] 
Source 
CVB 
5 Aminophenazone 3000 no [0.1] 1 [9] 
8 Amodiaquine 2450 yes 76 91.3 [9] 
12 Benzbromarone 150 yes 10 12.1 [9] 
13 Bromfenac 200 yes 1 43.8 int. 
17 Carbamazepine 1200 yes 2 8.6 [11] 
21 Cilazapril 5 no 67 nd  
24 Clozapine 900 yes 7 82.7 [9] 
39 Flutamide 750 yes 20 9.7 [9] 
44 Imiloxan 500 yes 9 40.8 int. 
52 Nefazodone 600 yes 51 43.3 int. 
53 Nevirapine 400 yes [0.1] 2.9 [9] 
70 Ritonavir 1200 no 4 47.7 [9] 
79 Ticlopidine 600 yes 20 89.5 [9] 
80 Tienilic acid 500 yes [0.1] 77.2 int. 
82 Tolcapone 600 yes 515.4 nd  
83 Troglitazone 600 yes 9 26.7 int. 
84 Valproic acid 4200 yes 19.2 9.3 [9] 
91 Zomepirac 600 no 5 7.2 [9] 
*[0.1]: no substrate depletion observed 
 int:  in house data 
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Table A3.1.2 
 
   Calculated properties Literature Values  
index name 
 max. 
dose 
[mg] 
logD6.0 PSA ka 
CL 
oral 
[L/h] 
Ref
. 
Foral* Ref. 
[I]in 
[mg/
L] 
low risk          
2 Acetyl salicylic 
acid 2000 1.34 51.1 2.96 87.5 [34] 0.63 [35] 39.8 
7 Amlodipine 10 1.14 83.0 1.65 22.5 [36] 0.81 [37] 0.2 
15 Caffeine 900 -0.12 48.3 1.85 4.7 [38] [1.0]  25.2 
31 Donepezil 10 1.16 37.2 3.48 9.7 [39] 0.95 [40]* 0.4 
35 Ethinylestradiol 0.0035 4.12 32.4 10.7 33.7 [41] 0.01 [42]* 0.0 
42 Gemfibrozil 900 3.59 39.2 7.98 15.1 [43] [1.0]  0.5 
47 Levofloxacin 750 -1.61 64.6 0.84 7.6 [44] [1.0]  10.5 
48 Lidocaine 105 -0.12 25.3 2.68 248.3 [45] 0.42 [45] 1.3 
55 Olanzapine 20 0.86 27.6 3.65 16.1 [46] 0.7 [47] 0.6 
56 Olmesartan 40 5.59 107 5.42 4.9 [48] 0.36 [49] 1.2 
61 Pioglitazone 45 4.62 60.6 8.14 3.3 [50] 0.83 [51] 3.7 
62 Pravastatin 80 1.63 94.7 1.63 263 [52] 0.18 [53] 0.3 
68 Rimonabant 20 2.67 42.1 5.49 4.4 [54] 0.18 [55]* 0.4 
71 Rosiglitazone 8 2.67 60.4 4.09 2.1 [56] 0.99 [57] 0.5 
81 Tocopherol 
acetate 20 12.30 29.0 206 20  [1.0]  42.8 
85 Valsartan 320 0.31 96.8 0.98 8 [59] 0.23 [60] 2.4 
88 Warfarin 15 2.13 49.1 4.05 26.6 [61] 0.93 [62] 0.6 
risk           
1 Acetaminophen 4000 0.36 41.3 2.45 19.6 [63] 0.87 [64] 96.8 
10 Atorvastatin 80 2.42 87.3 2.43 18.8 [65] 0.12 [53] 0.4 
19 Celecoxib 400 3.97 68.5 5.68 28.1 [66] [1.0]  24.1 
23 Clopidogrel 75 2.16 23.6 6.18 5.5e4 [67] [1.0]  4.8 
27 Diazepam 15 2.71 27.1 7.08 1.8 [68] [1.0]  1.4 
28 Diclofenac 200 1.28 40.6 3.43 26.6 [69] 0.65 [70] 4.9 
30 Diphenhydramin 300 1.19 12.1 5.26 48 [71] [1.0]  16.6 
36 Felbamate 3000 0.76 90.1 1.29 2.3 [72] [1.0]  94.3 
38 Fluoxetine 20 2.35 19.7 7.03 43 [73] [1.0]  1.5 
45 Imipramine 300 2.31 6.7 8.55 240 [74] 0.42 [74] 11.2 
46 Indomethacin 200 2.19 57.0 3.64 2.9 [75] 0.77 [76] 8.7 
59 Phenytoin 600 2.28 51.3 4.12 0.2 [38] 0.93 [77] 149 
65 Propranolol 480 0.92 35.7 3.27 325.5 [78] 0.01 [79]* 0.2 
75 Sulfa-
methoxazole 1600 -1.16 82.8 0.73 75.8 [80] 0.99 [81] 12.9 
77 Tacrine 160 0.55 30.5 3.12 1404 [82] 0.17 [83]* 0.9 
78 Tamoxifen 40 4.38 13.2 16.0 3.6 [84] 0.24 [85] 2.0 
87 Verapamil 480 1.76 59.5 3.00 371.7 [86] 0.90 [87] 13.4 
89 Zafirlukast 40 5.58 94.7 6.61 20 [88] [1.0]  20.0 
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Table A3.1.2 contd. 
 
   calculated properties Literature values   
index name 
 
max. 
dose 
[mg] 
logD6.0 PSA ka 
CL 
oral 
[L/h] 
Ref Foral* Ref 
[I]in 
[mg/L
] 
high risk          
5 Amino-phenazone 3000 0.58 26.8 3.35 2.2 [89] [1.0]  160.7 
8 Amodiaquine 2450 4.00 42.2 8.77 4140 [90] [1.0]  222.4 
12 Benz-bromarone 150 4.30 39.8 10.2 3.4 [91] [1.0]  17.6 
13 Bromfenac 200 3.08 66.6 4.27 7.3 [92] [1.0]  10.0 
17 Carbama-
zepine 1200 1.46 35.8 3.96 3.5 [93] 0.83 [94] 55.1 
24 Clozapine 900 1.57 27.1 4.72 18 [95] 0.48 [96] 23.2 
39 Flutamide 750 3.51 58.6 5.67 0.4 [97] [1.0]  122.1 
44 Imiloxan 500 1.15 31.0 3.83 655.7 [98] [1.0]  19.9 
52 Nefazodone 600 4.50 50.4 9.19 33.8 [99] 0.14 [100]* 8.7 
53 Nevirapine 400 3.55 47.4 6.89 3.9 [101] [1.0]  32.8 
70 Ritonavir 1200 2.97 108 2.1 17.3 [102] 0.7 [103] 21.2 
79 Ticlopidine 600 2.90 4.1 11.0 269.3 [104] [1.0]  68.3 
80 Tienilic acid 500 1.25 55.3 2.68 4.1 [105] [1.0]  19.0 
82 Tolcapone 600 1.80 86.6 1.96 7.1 [106] 0.6  [106] 10.8 
83 Troglitazone 600 4.96 73.1 7.50 29.8 [107] 0.43 [107] 20.6 
84 Valproic acid 4200 1.88 29.1 5.12 0.6 [108] 0.99 [108] 511.9 
91 Zomepirac 600 1.31 49.7 3.00 11.3 [109] [1.0]  20.9 
[1.0]: no value found; *F in rat (propranolol, rimonabant in monkey) 
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Abbreviations 
CL   Clearance 
CLint   Intrinsic clearance 
CVB   Covalent protein binding 
CYP   Cytochrome P450 
DILI   Drug-induced liver injury 
ER   Enhanced resolution 
EPI   Enhanced product ion 
F   Bioavailability 
Fa   Fraction absorbed 
FDp   Fraction of dose reaching the portal vein  
fm   Fraction metabolized 
Foral   Oral bioavailability 
GSH   Glutathione 
HLM   Human liver microsomes 
Iav   Systemic concentration 
Iin   Liver inlet concentration 
ka   Absorption constant 
LC-MS/MS  Liquid chromatography / tandem mass spectrometry 
LogD   Distribution coefficient 
logP   Partition coefficient 
NPV   Negative predictive value 
PI   Precursor ion 
PLA-DA  Partial least squares discriminant analysis 
PSA   Polar surface area 
Qh   Hepatic bloodflow 
RM   Reactive metabolite 
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4 SUMMARY AND OUTLOOK 
The term drug-induced liver injury (DILI) describes adverse effects upon therapeutic 
drug treatment. They are relatively rare, affecting only 1 of 104 - 106 patients, and 
remain mostly unpredictable. Due to development of severe hepatotoxicity or death, 
drugs causing DILI display a high risk for patients and have been withdrawn from the 
market or severely restricted in use. For the pharmaceutical industry late stage attrition 
due to DILI represents a big burden stretching development time and effort and 
generating potential risk at high costs. A better characterization of the disease pattern 
and its contributing factors is needed. Currently experimental tools to build preclinical 
mitigation strategies are sparse, but urgently required to help establish an improved 
risk assessment. One possible mechanism of toxicity involves the formation of 
chemically reactive metabolites (RM) which interact with cellular macromolecules or 
signaling pathways. A direct link between RM formation and DILI remains speculative 
in most cases. Numerous studies of affected drugs demonstrate the plausible 
involvement of RM formation and subsequent covalent binding to proteins. Still, RMs 
are not detected for all DILI drugs and RMs do not lead to DILI in every case. Thus, a 
synergistic effect of multiple (unknown) mechanisms is supposed to result in DILI. 
The aim of this work was to review mechanisms leading to DILI, consisting of RM 
formation and other potentially contributing risk factors such as oxidative stress, cyto- 
or mitochondrial toxicity. Results were critically evaluated in light of the predictivity for 
DILI and comprise a gap analysis of current approaches. Biomarkers are proposed as 
complementary endpoints. Development and validation of analytical methods were 
conducted for in vitro experiments followed by application of tool compounds to 
demonstrate the correlation to in vivo studies. 
For the in-depth analysis of bioactivation data and its correlation to DILI, a validation 
set of drugs was selected. These included three groups of compounds, namely those 
with severe manifestation of DILI, drugs with reported DILI cases and drugs with a 
history of safe use. Different models were drafted to evaluate quantitative covalent 
binding as predictive parameter for DILI. The hypothesis was that the intrinsic property 
of in vitro covalent binding is not a descriptive parameter, as exposure of a toxic drug 
or metabolite in the body is determined by pharmacokinetic factors. E.g., low clearance 
drugs might result in experimental false negative results when they are not significantly 
activated in vitro. Thus, pharmacokinetic properties such as plasma clearance or 
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hepatic inlet concentration were incorporated into the correlation analysis. A 
quantitative description of the models was established by sensitivity, specificity, 
precision and negative predictive value. As previously reported, a correlation between 
covalent binding, the daily dose and DILI was evident. This correlation further 
improved when adjusted for intrinsic clearance and substituting dose with the 
theoretical liver inlet concentration. It is further suggested to use glutathione adduct 
formation as surrogate for covalent binding. This approach was able to separate safe 
and high risk DILI drugs when evaluated in context of dose and clearance. The 
correlation did not hold true for medium risk drugs where a big overlap to safe drugs 
was noticeable. This may be due to equivocal drug classification or the fact that 
additional factors contribute to the development of DILI. 
One of the risk factors contributing to DILI is the excessive overproduction of reactive 
oxygen species (ROS), i.e. oxidative stress. Oxidative stress can be measured e.g. by 
cellular damage, biomarkers of lipid peroxidation or secondary signals like gene 
expression. Isoprostanes were chosen as biomarkers for further investigation. They 
derive from radical-catalyzed peroxidation of arachidonic acid. Selected isomers of 
this heterogeneous group were reported as biomarkers of ROS in the past. An online 
separation chromatography coupled mass spectrometry method was developed to 
simultaneously detect various isoprostanes and prostaglandins with a low limit of 
quantification. Analytical method validation allowed application of these biomarkers to 
a proof of concept study in primary rat and human hepatocytes. Results indicate a 
significant time and dose dependent cellular response for different isoprostane 
isomers by treatment with ferric nitrilotriacetic acid, a chemical known to cause 
oxidative stress. Furthermore, the value of isoprostanes as biomarkers of cellular 
oxidative stress was shown for DILI model compounds. The anticancer agent 
flutamide is known to cause hepatotoxicity, most likely by formation of reactive 
metabolites and impairment of mitochondrial function. Formation of imino-quinone 
intermediates may initiate redox cycling and cause excessive generation of ROS. In 
order to attenuate drug-induced ROS, hepatocyte cell culture was supplemented with 
pro-oxidant substrates for the in situ generation of hydrogen peroxide. Treatment of 
rat and human hepatocytes with flutamide induced oxidative stress as indicated by a 
time and dose dependent increase of isoprostane concentration. Other lipid 
peroxidation products, namely the hydroxynonenal (HNE) derived conjugates, HNE 
mercapturic acid (MA) and its reduced form dihydroxynonene MA, were found to be 
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augmented upon treatment with flutamide as well. These were included into the 
biomarker panel. Under the test conditions no cytotoxicity was present, emphasizing 
the potential of lipid peroxidation products to early detect upcoming liver damage in in 
vitro systems. The described biomarkers could be translated between species from 
rat to human in hepatocytes. Further, results in Fischer F344 rats revealed their 
applicability to in vivo and enabled their classification relative to other cellular oxidative 
stress markers. In rats, the antioxidant response pathway was investigated via 
quantitative determination of mRNA for cytoprotective enzymes. In rat hepatocytes 
and rat liver increased RNA expression levels for glutathione-S-transferase, heme 
oxygenase, and NADPH:quinone oxidoreductase were detected. This suggests 
adaptation of cell homeostasis upon oxidative stress induced damage prior to overt 
cellular or organ damage. It can be assumed that pro-oxidant processes result in 
pathophysiological changes contributing to manifestation of DILI. Thus, the 
characterization of bioactivation potentials and oxidative stress conditions as 
contributing factor to DILI may be appropriate to characterize DILI risk. The 
development of new analytical tools using state of the art mass spectrometry enabled 
quantitative biomarker analysis and glutathione adduct screening from the same 
sample. 
In conclusion, this work describes the advances and limitations of RM characterization 
as risk for DILI. It highlights the value of characterizing danger signals, e.g. induced 
by oxidative stress. Specifically, biomarkers derived from lipid peroxidation and cell 
signal analysis may support preclinical risk assessment. It further stresses the 
importance of integrated risk mitigation strategies that are able to capture a variety of 
relevant drug properties and the mechanism by which they modulate toxicity. It must 
be also taken into account that patient related risk factors are likely to play a major 
role in development of DILI. Therefore, it is necessary to judge elucidated pathways 
on their potential to cause inter-individual differences. To minimize the general risk of 
adverse effects including DILI, the predominant goal in drug discovery must be the 
optimization of pharmacokinetic drug properties to yield low dose and selective drugs. 
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5 ZUSAMMENFASSUNG UND AUSBLICK 
Der Begriff arzneimittelinduzierter Leberschaden (engl.: drug-induced liver injury [DILI]) 
beschreibt adverse Effekte, die durch Arzneimittelanwendung in therapeutischen 
Dosen ausgelöst werden. Diese treten relativ selten, bei nur 1 von 104 - 106 Patienten, 
auf und sind mehrheitlich unvorhersehbar. Aufgrund der Entwicklung 
schwerwiegender Hepatotoxizität und Letalität stellen DILI-auslösende Arzneimittel 
ein hohes Risiko für Patienten dar und müssen vom Markt genommen oder gravierend 
anwendungsbeschränkt werden. Ein Entwicklungsstopp in späten Phasen der 
klinischen Arzneimittelprüfung aufgrund von DILI bedeutet für die pharmazeutische 
Industrie eine große Belastung, die die Zeit und den Aufwand der Entwicklung 
vergrößert und potenzielles Risiko verbunden mit hohen Kosten generiert. Aus diesen 
Gründen ist eine bessere Charakterisierung des Krankheits-bildes und seiner 
Einflussfaktoren notwendig. Aktuell sind experimentelle Hilfsmittel zum Aufbau 
präklinischer Strategien zur Risikominimierung rar, jedoch zur Etablierung einer 
besseren Risikoabschätzung dringend erforderlich. Ein möglicher Mechanismus ist 
die Bildung von chemisch reaktiven Metaboliten (RM), die mit zellulären 
Makromolekülen oder Signalwegen interagieren können. Allerdings ist ein direkter 
Zusammenhang zwischen RM Bildung und DILI in den meisten Fällen bisher 
spekulativ. Zahlreiche Studien mit betroffenen Arzneistoffen zeigen die mögliche 
Beteiligung von RM und der daraus resultierenden kovalenten Bindung an Proteine. 
Dennoch sind RM nicht für alle DILI-Fälle nachgewiesen und es gibt Arzneistoffe, in 
denen RM nicht zu DILI führen. Daher wird ein synergistischer Effekt aus vielen 
(unbekannten) Mechanismen als Auslöser für DILI vermutet. 
Ziel dieser Arbeit war es, Mechanismen, die zu DILI führen, zu überprüfen; hierzu 
gehörten sowohl die Bildung von RM als auch andere potenzielle Risikofaktoren wie 
oxidativer Stress, zelluläre oder mitochondriale Toxizität. Ergebnisse wurden in 
Hinblick auf Prädiktivität für DILI bewertet und stellen eine sog. GAP-Analyse (engl. 
gap = Lücke) der bestehenden Ansätze dar. Hierfür werden Biomarker als 
komplementäre Endpunkte vorgeschlagen. Für diese wurden analytischen Methoden 
für in vitro Experimente entwickelt und validiert, die daraufhin für Modellsubstanzen 
angewendet und zu in vivo Studien korreliert wurden.  
Für die detaillierte Analyse von Bioaktivierungsdaten und ihrer Korrelation zu DILI 
wurde ein Validierungssatz von Substanzen ausgewählt. Dieser beinhaltete drei 
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Gruppen: Substanzen mit schwerwiegender DILI-Form, Substanzen, für mit DILI-
Fallberichte existieren und solche, die in Bezug auf DILI sicher angewendet werden 
können. Um kovalente Binding quantitativ als prädiktiven Parameter für DILI zu 
beurteilen,  wurden verschiedene Modelle entworfen. Diese basierten auf der 
Hypothese, dass die intrinsische Fähigkeit zu kovalenter Bindung in vitro als 
deskriptiver Parameter nicht ausreicht, da die Exposition einer toxischen Substanz 
oder ihres Metaboliten im Körper durch ihre Pharmakokinetik bestimmt wird. Zum 
Beispiel können Substanzen mit niedriger Stoffwechselrate zu einem falsch negativen 
Ergebnis führen, wenn sie in vitro nicht aktiviert werden. Daher wurden 
pharmakokinetische Eigenschaften wie Plasmaelimination oder hepatische 
Einströmungskonzentration für die Korrelationsanalyse einbezogen. Quantitativ 
wurden die Modelle durch Sensitivität, Spezifität, Präzision und negativen 
Vorhersagewert beschrieben. Wie im Vorfeld berichtet, war ein Zusammenhang 
zwischen kovalenter Bindung, der Dosis und DILI vorhanden. Die Korrelation wurde 
besser, wenn kovalente Bindung gegenüber der intrinsischen Clearance normalisiert 
oder die Dosis durch eine theoretische Portalvenenkonzentration ersetzt wurde. 
Weiterhin kann die Bildung von Glutathionaddukten als Surrogat für kovalente 
Bindung vorgeschlagen werden. Mit diesem Ansatz war es möglich, sichere 
Arzneistoffe von solchen der Hochrisikiogruppe zu trennen, wenn er im Kontext von 
Dosis und Clearance betrachtet wurde. Für die Substanzen der mittleren 
Risikokategorie galt dieser Zusammenhang nicht; hier war eine große 
Überschneidung zu den sicheren Substanzen vorhanden. Die Ursache hierfür könnte 
einerseits die Unsicherheit in der Klassenzuordnung sein oder die Tatsache, dass 
zusätzliche Faktoren bei der Entwicklung von DILI mitwirken. 
Einer der Risikofaktoren, die zu DILI beitragen, ist die exzessive Überproduktion von 
reaktiven Sauerstoffspezies (engl. reactive oxygen species [ROS]), also oxidativer 
Stress. Oxidativer Stress kann z.B. durch Zellschäden, Lipidperoxidation oder 
sekundäre Signale wie Genexpression gemessen werden. Für weitere 
Untersuchungen wurden Isoprostane als Biomarker ausgewählt. Diese stammen aus 
der radikalkatalysierten Peroxidation von Arachidonsäure. Einzelne Isomere dieser 
heterogenen Gruppe wurden schon in der Vergangenheit als Biomarker für ROS 
beschrieben. Es wurde eine kombinierte Methode für Festphasenextraktion und 
chromatographische Trennung mit massenspektrometrischer Detektion  entwickelt, 
die die gleichzeitige Analyse von diversen Isoprostanen und Prostaglandinen bei 
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niedrigem Quantifizierungslimit erlaubte. Die Validierung der Analytik ermöglichte in 
der Folge die Anwendung der Biomarker in einer Machbarkeitsstudie mit primären 
humanen - und Rattenhepatozyten. Die Ergebnisse mehrerer Isoprostanisomere 
zeigen eine signifikante zeit- und dosisabhängige zelluläre Reaktion auf Behandlung 
mit Eisennitrilotriazetat, einer Chemikalie, die oxidativen Stress auslöst. Weiterhin 
wurde auch für DILI Modellsubstanzen die Bedeutung von Isoprostanen als Biomarker 
für zellulären oxidativen Stress gezeigt. Das Krebstherapeutikum Flutamid ist dafür 
bekannt, Hepatotoxizität auszulösen, wahrscheinlich durch die Bildung von RM und 
Schädigung der mitochondrialen Funktion. Die Bildung von 
Iminochinonzwischenstufen könnte Redox-Cycling initiieren und dadurch exzessive 
Generierung von ROS triggern. Um die Hepatozyten auf den Effekt 
arzneistoffinduzierter ROS zu sensibilisieren, wurde die Zellkultur mit pro-oxidativen 
Substraten für die in situ Bildung von Wasserstoffperoxid ergänzt. Durch die 
Flutamidbehandlung von Ratten- und humanen Hepatozyten wurde oxidativer Stress 
ausgelöst, erkennbar durch einen zeit- und dosisabhängigen Anstieg der 
Isoprostankonzentrationen. Andere Lipidperoxidationsprodukte, namentlich die 
Hydroxynonenalderivate (HNE) HNE-Merkaptursäure (MA) und ihr reduziertes 
Analogon Dihydroxynonen-MA, zeigten ebenfalls eine Konzentrationserhöhung durch 
Flutamidbehandlung. Daher wurden sie zum Biomarkerset hinzugefügt. Unter den 
Testbedingungen konnte keine Zytotoxizität festgestellt werden, eine Tatsache, die 
das Potential der Lipidperoxidationsprodukte, entstehende Leberschäden in in vitro 
Systemen früh zu erkennen, hervorhebt. Die beschriebenen Biomarker zeigten 
Übertragbarkeit zwischen den Spezies Ratte und Human in Hepatozyten. Des 
Weiteren bezeugten Ergebnisse in Fischer F344 Ratten deren Anwendbarkeit in vivo 
und ermöglichten eine Einordnung relativ zu anderen zellulären Markern für oxidativen 
Stress. In Ratten wurde die antioxidative Reaktion durch quantitative Bestimmung von 
mRNA Expressionsleveln für zytoprotektive Enzyme untersucht. Hepatozyten und 
Leberproben von Ratten zeigten eine erhöhte Expression der RNA für Glutathion-S-
Transferasen, Hämoxygenasen und NADPH:Chinon Oxido-reduktasen. Dieses deutet 
auf eine Adaption der Zellhomöostase an Schäden induziert durch oxidativen Stress 
hin, die sich bemerkbar macht, bevor ein offensichtlicher Zell- oder Organschaden 
auftritt. Daraus kann geschlossen werden, dass prooxidative Prozesse zu 
pathophysiologischen Veränderungen führen, welche zur Manifestierung von DILI 
beitragen. Deswegen ist die Charakterisierung von Bioaktivierungspotential und 
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oxidativem Stress als Beitrag zu DILI für eine Risikobewertung sinnvoll. Die 
Entwicklung von neuen analytischen Verfahren mit Massenspektrometern aktueller 
Technik ermöglicht zum Beispiel quantitative Biomarkeranalyse und Messung von 
Glutathionaddukten aus derselben Probe. 
Zusammengefasst beschreibt diese Arbeit die Fortschritte und Limitationen der 
Charakterisierung von RM als Risikofaktor für DILI. Sie stellt den Wert der Analyse 
von Warnsignalen, die z.B. durch oxidativen Stress ausgelöst werden können, heraus. 
Besonders Biomarker, die aus der Peroxidation von Lipiden hervorgehen, und die 
Analyse von Zellsignalwegen können die präklinische Risikobewertung unterstützen. 
Die Arbeit betont weiterhin die Bedeutung von integrativen Strategien zur 
Risikominimierung, die in der Lage sind, viele relevante Substanzeigenschaften zu 
erfassen und damit auch die Mechanismen, durch die sie Toxizität modulieren. Es 
muss jedoch auch berücksichtigt werden, dass wahrscheinlich patientenabhängige 
Risikofaktoren eine bedeutende Rolle in der Entwicklung von DILI spielen. Daher ist 
es notwendig, beteiligte Mechanismen in Hinblick auf ihr Potential, interindividuelle 
Unterschiede zu verursachen, zu bewerten. Um das generelle Risiko für adverse 
Effekte (einschließlich DILI) zu reduzieren, muss es das erste Ziel der 
Arzneistoffentwicklung sein, niedrig dosierte und selektive Substanzen durch die 
Optimierung pharmakokinetischer Eigenschaften zu erlangen. 
